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ABSTRACT 
Acute hepatopancreatic necrosis disease (AHPND) causes mass mortalities in 
farmed penaeid shrimp and has proven difficult to control using typical disease control 
measures.  The causative agent of AHPND has been identified as Vibrio 
parahaemolyticus strains possessing the 69 kbp plasmid pVPA3-1 containing genes 
homologous with Photorhabdus insect-related (Pir) toxin-like genes (pirA- and pirB-
like).  Probiotics have been used successfully in shrimp aquaculture to control disease 
outbreaks caused by pathogenic Vibrio, but there are currently no probiotics available 
that have been proven to control AHPND.  The goal of this study was to screen and 
characterize marine bacterial isolates as potential agents to prevent Artemia nauplii 
and Litopenaeus vannamei post-larvae (PL) mortality by the pathogen Vibrio 
parahaemolyticus.  Twelve candidate probiotic organisms were tested in an Artemia 
sp. model.  Phaeobacter inhibens was the only candidate probiont that significantly 
increased the survival of Artemia nauplii challenged with AHPND V. 
parahaemolyticus (p<0.001).   Candidate probionts Pseudoalteromonas piscicida, 
Pseudoalteromonas flavipulchra, and Pseudoalteromonas arabiensis were lethal to 
Artemia nauplii (p<0.001).  Six species of candidate probiotic organisms were tested 
in L. vannamei.  P. inhibens was the only candidate probiont tested which was not 
harmful to L. vannamei PLs and significantly increased the survival of PLs challenged 
with AHPND V. parahaemolyticus (p<0.001).  Genome analysis of V. 
parahaemolyticus PSU5579 revealed the presence of the multiple putative virulence 
genes including nine hemolysins, six secreted proteases, and six secretion systems 
including one T3SS and two T6SS.  The genome also contains the 69 kbp pVPA3-1 
plasmid encoding the pirA- and pirB-like toxin genes.  Genome analysis of 
Bowmanella denitrificans JL63 revealed several gene clusters potentially involved in 
the production of the following antibacterial compounds: colicin V (or bacteriocin), 
lanthionine, the broad-spectrum antibacterial protein marinocine encoded by the 
lodAB operon, a secreted hemolysin-type calcium-binding bacteriocin, lantipeptide, 
bacteriocin, and a nonribosomal peptide. 
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PREFACE 
The following thesis has been prepared in manuscript format according to the 
guidelines of the Graduate School of the University of Rhode Island.  This thesis 
contains a literature review and three manuscripts. 
The first manuscript “Biocontrol of acute hepatopancreatic necrosis disease 
(AHPND)” will be submitted to BMC Microbiology. 
The second manuscript “Draft genome sequence of Vibrio parahaemolyticus 
PSU5579, isolated during an outbreak of acute hepatopancreatic necrosis disease 
(AHPND) in Thailand.” will be submitted to Genome Announcements. 
The third manuscript “Draft genome sequence of Bowmanella denitrificans 
JL63, a bacterium isolated from whiteleg shrimp (Litopenaeus vannamei) that can 
inhibit the growth of Vibrio parahaemolyticus” will be submitted to Genome 
Announcements. 
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Introduction 
 
In 2009 an emerging disease now known as acute hepatopancreatic necrosis 
disease (AHPND) began to affect penaeid shrimp farms in southern China [1, 2].  The 
disease has spread to Vietnam, Malaysia, Thailand, and Mexico and global losses from 
AHPND are estimated to amount to more than one billion US dollars annually [2-5].  
AHPND causes serious production losses in affected areas which negatively impacts 
local employment, social welfare, and international markets [6].  The causative agent 
of AHPND has been identified as Vibrio parahaemolyticus strains possessing the 69 
kbp plasmid pVPA3-1 containing genes homologous with Photorhabdus insect-related 
(Pir) toxin-like genes (pirA- and pirB-like) [2, 7, 8].  AHPND has proven difficult to 
control using typical disease control measures such as water disinfection and antibiotic 
treatment [9, 10]. 
Beneficial microbes known as probiotics have been used to improve the health 
and disease tolerance of terrestrial farm animals since the 1940s, and research on 
probiotics in aquaculture has continued to increase since the late 1980s [11-14].  
Studies have shown that probiotics can be used in aquaculture to prevent diseases in a 
variety of farmed species while also improving harvest yields [14-21].  Probiotics can 
provide various benefits in aquaculture including improvement of water quality, 
enhancement of nutrition of host species, reduced incidence of diseases, higher 
survival rates, and improved host immune response [15, 16, 22].  Probiotics have been 
used successfully in shrimp aquaculture to control disease outbreaks caused by 
pathogenic Vibrio spp. [14-18] and may have the potential to control AHPND.  
Probiotics provide an alternative to the use of antibiotics in aquaculture, which have 
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become increasingly controversial and ineffective due to the emergence of antibiotic 
resistance in bacteria [15, 23-25].  Members of the genus Phaeobacter have been 
shown to be effective probiotic organisms by protecting cod and turbot larvae from the 
pathogen Vibrio anguillarum [26, 27], as well as eastern oyster (Crassostrea 
virginica) larvae from the pathogens Aliiroseovarius crassostreae CV919-312
T
 and 
Vibrio coralliilyticus RE22 [19, 28].  The marine bacterium Phaeobacter inhibens 
S4Sm is an excellent biofilm former [28], produces the broad-spectrum antibiotic 
tropodithietic acid (TDA) [28], can quench/inhibit the quorum sensing-dependent 
production of the virulence factor protease in V. coralliilyticus RE22 [29], and is non-
toxic to eukaryotic organisms [30], which makes it an ideal candidate for the control 
of bacterial diseases in aquaculture such as AHPND. 
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Main Body 
Acute Hepatopancreatic Necrosis Disease (AHPND) 
Aquaculture is the world’s fastest growing food production sector with 
cultured shrimp increasing at an annual rate of 16.8 % [31].  In 2007, shrimp harvested 
from aquaculture surpassed wild-caught shrimp, and in 2013, aquaculture produced 
4.45 million metric tons of shrimp [32].  As of 2012, the shrimp farming industry was 
worth an estimated $19.4 billion [32].    Southeast Asia and China have the largest and 
most productive shrimp farming regions in the world with 77% of globally produced 
shrimp coming from Asia [32].  In 2009 an emerging disease first called early 
mortality syndrome (EMS) began to affect shrimp farms in southern China [1].  The 
disease has recently been given a more descriptive name, acute hepatopancreatic 
necrosis disease (AHPND) [2].  Since its emergence, the disease has spread to 
Vietnam, Malaysia, Thailand, and Mexico [2-4].  AHPND affects both whiteleg 
shrimp (Litopenaeus vannamei) and black tiger shrimp (Penaeus monodon) and can 
lead to 100% mortality in affected populations [3].  The causative agent of AHPND 
has been identified as V. parahaemolyticus strains possessing the 69 kbp plasmid 
pVPA3-1 containing genes homologous with Photorhabdus insect-related (Pir) toxin-
like genes (pirA- and pirB-like) [2, 7].   
Initial studies determined that the pathology of AHPND is limited to the 
hepatopancreas (HP) which suggests that the disease may have a toxin-mediated 
etiology [19, 33].  It has also been shown that cell-free supernatant from V. 
parahaemolyticus strains possessing pVPA3-1 can cause AHPND, supporting the 
conclusion that a toxin is associated with the disease [19].  AHPND develops 
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approximately eight days after ponds are stocked with shrimp post-larvae (PLs) and 
severe mortalities occur within the first 20-30 days [19, 33].  Early signs of AHPND 
include a pale to white HP, reduced HP size, empty stomach, and empty midgut 
(Figure 1) [19].  Histological analysis of the HP has revealed three stages of AHPND: 
initial, acute, and terminal.  In the initial stage, the epithelial cells of the HP are 
elongated into tubular lumen and there is a reduction of the vacuole size in R 
(resorptive) and B (blister like) cells [33].  In the acute stage, the tubular epithelium is 
necrotic with severe desquamation of the cells showing hemocytic infiltration as a 
response to the necrotic epithelium [33].  In the terminal stage of the disease, the HP 
tubules show a severe inflammatory response and the tubular epithelium becomes 
entirely necrotic with massive sloughing of epithelial cells (Figure 2) [33-35].  At this 
stage, low levels of Vibrio can be found in the necrotic tissue in the HP and higher 
loads of Vibrio can be found in the stomach [33].  Additionally, there is increased 
hemocyte infiltration and black streaks or spots develop in the HP due to melanin 
deposition from hemocyte activity [19-33].  The absence of an inflammatory response 
that is usually elicited by a pathogen during the early stages of AHPND strongly 
supports the conclusion that this disease has a toxin-mediated etiology [2]. 
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Figure 1. (a) Photographs of hepatopancreases from healthy L. vannamei shrimp 
(upper two) and shrimp naturally infected with AHPND (arrows). (b) The 
hepatopancreas without external membrane shows atrophy and white color [33]. 
 
 
Figure 2. Histopathological analysis of hepatopancreas of shrimp challenged by 
immersion with AHPND V. parahaemolyticus. Necrosis and sloughing (arrows) of 
hepatopancreas were observed when challenged at 10
5
 CFU/ml (c), and these signs 
were more severe at 10
6
 CFU/ml (d); however, non-AHPND pathology was found at 
10
3
 CFU/ml (a) and 10
4
 CFU/ml (b) [35].  Sloughing can be observed as cells round 
up and detach into the tubule lumens. 
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AHPND causes serious production losses in affected areas which negatively 
impacts local employment, social welfare, and international markets [6].  Global 
losses from shrimp disease are estimated to amount to around three billion US dollars 
annually [31] with losses from AHPND amounting to more than one billion US 
dollars annually [5].  Disease prevention can be challenging for shrimp farmers 
because most farmers do not have the resources to treat seawater before it is used to 
fill their ponds [36] and by the time shrimp are showing signs of AHPND, it is 
difficult to treat as antibiotic treatment has proven unsuccessful in most cases [10].  
Additionally, treating water sources with chlorine, ozone, or UV before stocking does 
not provide total sterility [9].  Further, disinfection of water perturbs the natural 
microbial balance and leaves the environment open to opportunistic bacteria which 
survived disinfection.  This can actually favor the growth of Vibrio as Vibrio grow 
rapidly after their competitors are removed [37].  V. parahaemolyticus has been 
reported to have a generation time as short as 12 minutes [38]. 
Current recommendations to prevent AHPND outbreaks in shrimp farms 
include the use of greenwater systems [39] or the application of biocontrol strategies 
such as probiotics [5], phage [40], or Bdellovibrio-and-like organisms (BALOs) [41].  
It has been observed that AHPND is less prevalent in ponds colonized by copepods 
[39].  Copepods require a constant supply of phytoplankton and bacteria as feed, so 
their presence in an indicator of a mature ecosystem [42].  The use of greenwater 
systems has also been observed to reduce the incidence of AHPND [39].  Greenwater 
systems are characterized by a mature micro-algal and bacterial community.  These 
systems have been shown to maintain decreased Vibrio levels and decreased animal 
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mortality [43, 44].  The beneficial effect of greenwater systems can be attributed to the 
algal and bacterial production of antibacterial substances [45, 46] and compounds 
which quench/inhibit quorum sensing-dependent production of virulence factors in 
pathogens [47].  Additionally, the bacteria in greenwater systems compete with 
pathogens for available nutrients and occupy niches which would otherwise be left 
open for invading pathogens [46].  Occurrences of overgrowth of pathogenic bacteria 
such as Vibrio spp. in shrimp grow-out ponds can be reduced by minimizing 
disturbances such as water disinfection which lead to sudden variations in nutrient 
levels, and by colonizing pond water with nonpathogenic bacteria and/or algae [48]. 
Probiotic bacteria have been used successfully in shrimp aquaculture to control 
disease outbreaks caused by pathogenic Vibrio spp. [14-16].  A recent study 
determined that the probiotics which are currently commercially available to shrimp 
farmers in Malaysia are not effective at controlling AHPND [49].  More research 
needs to be conducted to develop and test new probiotic formulations which may have 
the potential to control AHPND.  The use of phage has also been proposed as a 
potential strategy to control AHPND, and a virulent Siphoviridae phage, pVp-1, has 
been shown to have effective bacteriolytic activity against 74% of AHPND strains of 
V. parahaemolyticus tested, but has yet to be tested in an aquaculture setting [40].  
Another promising biocontrol strategy to prevent AHPND involves the use of BALOs.  
A recent study isolated a BALO, identified as Bacteriovorax sp. BV-A, from a 
sediment samples in a shrimp farm in Thailand, which could kill all AHPND strains of 
V. parahaemolyticus tested as well as Vibrio vulnificus, Vibrio cholerae, and Vibrio 
alginolyticus [41].  Bacteriovorax sp. BV-A was also shown to increase the survival of 
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L. vannamei PLs challenged with AHPND V. parahaemolyticus by 50% [41].  In field 
studies, BALOs in combination with photosynthetic bacteria have been shown to 
provide increased survival rates of Chinese mitten crab (Eriocheir sinensis) and 
decreased Vibrio concentrations in cultured pufferfish (Fugu obscurus) [50].  The use 
of BALOs is a promising prospect for the control of diseases caused by bacterial 
pathogens in aquaculture. 
 
Vibrio parahaemolyticus 
Vibrio is a genus of Gram-negative motile marine bacteria of the family 
Vibrionaceae within the Gammaproteobacteria [51].  Members of this genus are 
facultative anaerobes with a curved-rod shape [52].  Vibrio species can be found in a 
wide range of aquatic environments, including the water column, in association with 
hosts (both pathogenic and symbiotic), and even in extreme habitats (hydrothermal 
vents) [53].  Pathogenicity in Vibrio is not species dependent, but rather strain specific 
as different strains of the same species can cause diseases in different hosts, or can be 
nonpathogenic [54, 55].  Many species of Vibrio are pathogenic and can cause disease 
in humans (e.g. V. cholerae, V. parahaemolyticus, V. vulnificus, V. alginolyticus) [53, 
56, 57], fish (V. anguillarum, V. alginolyticus, V. harveyi) [53, 58], bivalves (V. 
coralliilyticus, V. tubiashii, V. parahaemolyticus, V. harveyi, V. alginolyticus) [59], 
coral (V. coralliilyticus) [60], or shrimp (V. parahaemolyticus, V. harveyi, V. 
campbellii, V. alginolyticus) [53].  The aquaculture industry suffers multibillion-dollar 
losses due to these pathogens annually [5, 53, 61]. 
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Vibrio spp. are known to possess a number of virulence factors including 
enterotoxins, cytotoxins such as the multifunctional-autoprocessing repeats-in-toxin 
(MARTX) toxins which use a type I secretion system (T1SS), siderophores, adhesion 
factors/biofilm formation (type I pili), extracellular polysaccharides, hemagglutinins, 
type III secretion systems (T3SS), type VI secretion systems (T6SS), and lytic 
enzymes including hemolysins, proteases, lipases, and chitinases, most of which use 
type II secretion systems (T2SS) [53, 62-64].  Virulence gene expression in Vibrio is 
regulated by quorum sensing and has been studied extensively in V. harveyi [53, 64].  
V. harveyi uses a three-channel quorum-sensing system (Figure 3), secreting chemical 
signal molecules that include HAI-1 (Harveyi autoinducer 1), AI-2 (Autoinducer 2), 
and CAI-1 (Cholera autoinducer 1) [53].  The concentration of these molecules in the 
extracellular environment is proportional to cell density.  These autoinducers are 
detected at the cell surface by membrane bound histidine sensor kinase proteins that 
feed a phosphorylation ⁄ dephosphorylation signal transduction pathway which 
controls the production of the quorum-sensing master regulator protein LuxR (V. 
harveyi)/OpaR (V. parahaemolyticus) [53].  LuxR/OpaR directly activates the Lux 
operon, whereas most of the other genes regulated by quorum sensing are controlled 
indirectly [53].  Several species of Vibrio, including V. cholerae and V. 
parahaemolyticus, have virulence factors which are controlled by the ToxR regulon 
[53].  In V. cholerae, the ToxR regulon controls the expression of the ctx gene 
encoding the cholera toxin [53].  In V. parahaemolyticus the toxR operon controls the 
expression of the thermostable direct hemolysin gene (tdh) as well as the T3SS [65, 
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66].  The toxR operon is found in both clinical and environmental isolates of V. 
cholerae and V. parahaemolyticus [67]. 
 
 
Figure 3. Quorum sensing in Vibrio harveyi. The LuxM, LuxS and CqsA enzymes 
synthesise the autoinducers HAI-1, AI-2 and CAI-1, respectively. These autoinducers 
are detected at the cell surface by the LuxN, LuxQ and CqsS two-component receptor 
proteins, respectively. Detection of AI-2 by LuxQ requires the periplasmic protein 
LuxP. (a) In the absence of autoinducers, the receptors autophosphorylate and transfer 
phosphate to LuxO via LuxU. Phosphorylation activates LuxO, which together with 
σ54 activates the production of five small regulatory RNAs (sRNAs). These sRNAs, 
together with the chaperone Hfq, destabilise the mRNA encoding the transcriptional 
regulator LuxRVh. Therefore, in the absence of autoinducers, the LuxRVh protein is not 
produced. (b) In the presence of high concentrations of the autoinducers, the receptor 
proteins switch from kinases to phosphatases, which results in dephosphorylation of 
LuxO. Dephosphorylated LuxO is inactive and, therefore, the sRNAs are not formed 
and the transcriptional regulator LuxRVh is produced. P, phosphotransfer [53]. 
 
Vibrio parahaemolyticus is commonly found in marine coastal waters and 
estuarine environments including water, sediment, suspended particles, plankton, fish 
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and shellfish [53].  Strains of this species are a leading cause of seafood-associated 
bacterial gastroenteritis globally and can also cause eye, ear, and wound infections 
[68].  While most environmental strains of V. parahaemolyticus are not pathogenic to 
humans, strains possessing the tdh and trh genes and the T3SS2 gene cluster are 
pathogenic [69, 70].  Strains of V. parahaemolyticus are also an important shrimp 
pathogen and have been identified as the causative agent of AHPND.  One of the 
challenges of preventing and treating AHPND is the high frequency of antibiotic 
resistance found in V. parahaemolyticus isolates.  Jiang et al. [71] found that 100% of 
the V. parahaemolyticus strains they isolated in China were resistant to ampicillin and 
cephazolin and 43.7% were resistant to streptomycin.  Shaw et al. [72] found that 68% 
of V. parahaemolyticus strains isolated in Maryland, USA were resistant to penicillin 
and Al-Othrubi et al. [73] found that 21.5% of V. parahaemolyticus strains isolated in 
Malaysia were resistant to ciprofloxacin.  Additionally, Kongrueng et al. [74] tested 
AHPND strains of V. parahaemolyticus isolated in Thailand and found that all of these 
isolates were resistant to ampicillin and erythromycin. 
AHPND strains of V. parahaemolyticus have been identified as those 
possessing the 69 kbp plasmid pVPA3-1 containing genes homologous with 
Photorhabdus insect-related (Pir) toxin-like genes (pirA- and pirB-like) [2, 7, 8].  
These genes are located within a 3.5 kbp fragment flanked by inverted repeats of a 
transposase-coding sequence (1 kbp) which is a mobile genetic element that can 
induce horizontal gene transfer [2].  The GC content of the pirA- and pirB-like genes 
is only 38.2%, which is considerably lower than that of the rest of the plasmid 
(45.9%), suggesting that these genes were recently acquired [2].  Similar to the Pir 
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toxins that affect insects, the Pir-like toxins act as binary proteins, which form a 
heterodimer and both pirA- and pirB-like genes are required for pathogenesis [2, 8, 
75].  The crystal structure of the PirAB-like heterodimer has similar structural 
topology to that of the Bacillus Cry insecticidal toxin-like proteins, despite the low 
sequence identity (<10%), which suggests that the putative PirAB-like toxin might 
emulate the functional domains of the Cry protein and its pore-forming activity [75].  
While the PirA- and PirB-like toxins affect the hepatopancreas in shrimp, the Pir 
toxins primarily affect the midgut of insects, which may suggest different mechanisms 
of action [2]. 
While AHPND strains of V. parahaemolyticus have been shown to possess 
between 1 and 121 copies of the pVPA3-1 plasmid per cell [2, 8], the copy number of 
this plasmid does not correlate with virulence [8].  Instead, the amount of secreted 
PirA- and PirB-like proteins determines virulence to shrimp [8].  AHPND strains of V. 
parahaemolyticus have been shown to possess other virulence factors as well, 
including T3SS1, T6SS1, and T6SS2 genes [74].  Additionally, a unique sequence 
encoding a type IV pilus has been found in the genomes of AHPND strains of V. 
parahaemolyticus isolated in Thailand and Mexico [7, 76], but was not detected in 
strains isolated in India [34].  It has also been shown that AHPND strains of V. 
parahaemolyticus lack the tdh and trh genes [7, 8, 19, 33, 34] as well as the T3SS2 
gene [7, 34, 74] required for pathogenesis in humans, indicating that these strains are 
not human pathogens.  The role of virulence factors other than the PirA- and PirB-like 
toxins in the pathogenesis of AHPND strains of V. parahaemolyticus to shrimp has yet 
to be determined. 
14 
 
Probiotics in aquaculture 
 For more than 70 years, beneficial microbes known as probiotics have been 
used to improve the health and disease tolerance of terrestrial farm animals such as 
swine and chickens [11-13].  Probiotics are defined as “live microorganisms, 
conferring a healthy benefit to the host when being consumed in adequate amounts” 
[77].  Probiotics are now widely used for enhancing production of land animals due to 
the fact that they are better, cheaper, and more effective in promoting animal health 
than antibiotics or chemical substances [21].  Research on the use of probiotics in 
aquaculture dates back to the late 1980s and has continued to increase since then [14].  
Studies have shown that probiotics can be used in aquaculture to prevent diseases in 
bivalves (oysters, scallops), fish (salmon, cod, trout, halibut, turbot, catfish), and 
crustaceans (shrimp, Artemia spp.) [14-18, 20, 21].  Although probiotics can prevent 
disease when applied prophylactically, they are not meant to be used therapeutically 
and are unlikely to cure animals which are already infected with a pathogen [78, 79]. 
Currently the main rate limiting factor in the shrimp aquaculture industry is 
disease control.  Intensive (high-density) shrimp culture systems have become 
common practice because they produce substantially higher shrimp yields than do 
semi-intensive systems [80].  This intensification comes at a cost however, and results 
in stressful environmental changes which can cause problems for shrimp [81] and also 
increase their susceptibility to disease [82].  Although vaccines have been developed 
against several bacterial diseases in fish, such vaccines are not successful in shrimp or 
any other invertebrates due to the lack on an adaptive immune system [20].  In 
aquaculture, bacterial disease is generally controlled through water disinfection and 
15 
 
the application of antibiotics both prophylactically and therapeutically.  The use of 
antibiotics in aquaculture has become increasingly controversial and ineffective due to 
the emergence of antibiotic resistance in bacteria [15, 23-25].  Water disinfection also 
has limited success and in some cases may actually increase the likelihood of an 
outbreak, most notably in controlling diseases caused by Vibrios spp. such as AHPND 
[9, 10, 39].  Additionally, disinfecting water with chlorine has been shown to increase 
the proportion of multiple antibiotic resistance bacteria [83]. 
 The overuse of antibiotics in aquaculture has become a major concern due to 
the emergence of antibiotic resistance in bacteria and the potential for residual 
contamination in harvested fish and shellfish.  The aquaculture industry uses massive 
quantities of antibiotics which are released into the environment [24, 37].  For 
example, antibiotic usage in shrimp farms in Thailand in 1994 was estimated to be as 
much as 500 – 600 tonnes [37].  The leaching of these antibiotics into the environment 
contributes to the development of antibiotic resistance determinants in bacteria which 
can be spread to other species by horizontal gene transfer [24, 84].  These 
determinants can spread by horizontal gene transfer to bacteria of the terrestrial 
environment as well, including human and animal pathogens [24].  Studies have 
shown that antibiotic resistance determinants of Salmonella enterica serotype 
Typhimurium DT104, which caused several outbreaks of salmonellosis in humans and 
animals in Europe and the USA, likely originated in aquaculture settings of the Far 
East [24].  One study found that in the presence of tetracycline concentrations below 
the minimum inhibitory concentration (MIC), the rate of gene transfer between V. 
cholerae and Aeromonas salmonicida increased 100-fold [84].  Celli et al. [85] 
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proposed a molecular mechanism which may explain this increased rate of gene 
transfer in the presence of tetracycline.  Transfer of the conjugative transposon Tn916, 
possessing the tetracycline resistance determinant tetM, requires excision of the 
element and is dramatically increased in the presence of tetracycline [85].  
Tetracycline-based transcriptional attenuation of palorf12 allows for transcription of 
orf7 and orf8 from the tetM promoter [85].   ORF7 and ORF8 then activate the 
promoter Porf7 which directs the expression of the transfer functions in the transposon 
allowing for transfer of the element [85]. 
There is also public health concern over potential exposure of human 
consumers to antibiotic residues or other chemical contaminants in shrimp harvested 
from aquaculture [86].  Undetected consumption of antibiotics in food can cause 
allergy and toxicity problems, alter normal flora and increases susceptibility to 
infections, and select for antibiotic-resistant bacteria [24].  In 2006, there was an 
antibiotic residue crisis in the flatfish industry in China where 25,000 tonnes of turbot 
could not be sold, costing the industry an estimated 200 million Euro [50].  For these 
reasons, the use of probiotics in aquaculture is becoming an increasingly popular 
alternative to the use of antibiotics [15]. 
Probiotics provide several benefits in aquaculture including improvement of 
water quality, enhancement of nutrition of host species, reduced incidence of diseases, 
higher survival rates, and improved host immune response [15, 16, 22].  Although 
there have been many studies on probiotics in aquaculture, they are still not widely 
used.  Greenwater systems are a new water management strategy which use mature 
microalgal and bacterial communities and have been shown to have reduced Vibrio 
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levels and increased animal survival rates [43, 44].  Probiotics can be used not only as 
a biocontrol strategy, but can also be used in conjunction with algae treatment to make 
greenwater systems.  In aquaculture, probiotics are typically added to the feed or 
directly into the culture water [15].  Probiotics have been used successfully in shrimp 
aquaculture to control disease outbreaks caused by pathogenic Vibrio spp. while also 
improving harvest yields [14-18].  The most common probiotics used in aquaculture 
are photosynthetic bacteria (purple non-sulfur bacteria), antagonistic bacteria 
(Pseudoalteromonas spp., Flavobacterium spp., Alteromonas spp., Phaeobacter spp., 
Bacillus spp.), microorganisms for improving digestion (lactic acid bacteria and 
yeast), bacteria for improving water quality (nitrifying bacteria, denitrifiers), and 
predatory bacteria that kill other bacteria (e.g. BALOs) [50]. 
 Candidate probiotic organisms are typically selected based on their ability to 
produce antibacterial and/or antivirulence compounds.  These compounds give an 
ecological advantage to the producing bacteria against other microorganisms, and may 
also provide an advantage against bacteriovorous eukaryotic predators [30].  Some 
organisms that have been shown to inhibit the growth of bacterial pathogens also 
produce compounds that are toxic to eukaryotic organisms [30, 87, 88].  These 
organisms should tested thoroughly before being applied in aquaculture as they might 
cause adverse effects on the farmed animals, their prey species (algae, rotifers, or 
Artemia spp.), or the humans who consume them.  Therefore, the toxicity of the live 
bacterial cultures on the target organisms should be tested for any adverse effects 
before being applied commercially.  The candidate probiotics should be used to 
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challenge the target species under conditions which mimic the aquaculture setting 
before being tested in large scale.   
Artemia spp. have been used as a model organism not only for toxicology 
studies but also to test the effectiveness of probiotic bacteria and the role of quorum 
sensing in pathogenesis [30, 89-93].  Artemia spp. are useful model organisms because 
they adapt easily to changes in nutrients, salinity, temperature, and oxygen, are easy to 
culture, are resistant to manipulation, and have a short life cycle [94].  Toxicology 
studies using Artemia sp. to evaluate potential probiotic organisms have shown that 
both P. inhibens and Ruegeria mobilis are innocuous to these organisms while 
Pseudoalteromonas piscicida, Pseudoalteromonas rubra, Photobacterium 
halotolerans, and V. coralliilyticus are lethal and therefore should not be used as 
probiotics in aquaculture [30]. 
 The success of probiotic organisms can be attributed to several specific 
properties: 1) Improvement of water quality through the reduction of ammonia, nitrate, 
nitrite, phosphate, and carbon [95].  2) Antagonistic activity through the production of 
compounds which inhibit the growth of pathogenic bacteria.  Antagonistic bacteria 
have been shown to significantly decrease the concentration of Vibrio in shrimp ponds 
[96].  The production of inhibitory compounds against pathogens in vitro does not 
guarantee that potential probiotic organisms will be effective in vivo [97], but is still 
an important property of probiotic organisms which are effective [28, 95].  3) 
Competition for attachment sites which is likely to serve as the first barrier of defense 
against invading pathogenic bacteria [28, 95].  4) Competition for nutrients or 
available energy.  Verschuere et al. [89] showed that pre-colonization of Artemia sp. 
19 
 
culture water with non-antagonistic probiotic bacteria protected Artemia sp. from the 
pathogenic effects of a Vibrio proteolyticus and hypothesized that this protection may 
be due to competition with the pathogen for available nutrients.  5) Enhancement of 
host digestion through the production of enzymes which can break down chitin, starch, 
protein, cellulose, and lipids [16].  6) Stimulation of host immune response [15].  
Although shrimp lack an adaptive immunity, they still possess an innate immune 
system that effectively protects them from harmful microorganisms and probiotic 
treatment has been shown to modulate the cellular and humoral immune responses in 
shrimp [95].  7) Production of siderophores which compete with pathogens for ferric 
iron in the iron-limited environment of the host [15].  8) Production of acyl-
homoserine lactones (AHLs) which quench/inhibit the quorum sensing-dependent 
production of virulence factors in pathogens [29, 95].  Quorum sensing has been 
shown to be one of the virulence mechanisms of many pathogenic bacteria, including 
V. harveyi and V. parahaemolyticus [53, 98].  Organisms that are not harmful to host 
species and possess some, if not all, of these properties make ideal candidates for use 
as probiotics in aquaculture. 
 
Phaeobacter inhibens S4Sm 
The Roseobacter clade consists of organisms that occupy diverse marine 
niches and colonize both biotic and abiotic surfaces including sediments, 
phytoplankton, invertebrates, and vertebrates [28, 99-102].  This clade is an important 
member of the marine microbiota, accounting for ~4 % to as much as ~40 % of 
bacterial DNA from the ocean depending on location, and plays an important role in 
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the organic sulfur cycle of the ocean by degrading dimethylsulfoniopropionate 
(DMSP) [100, 103-106].  Roseobacter clade members are also dominant primary 
surface colonizers [102, 107, 108] and are known to produce biologically active 
secondary metabolites [28, 109-112].  These secondary metabolites play an important 
role in the symbiotic relationship between Phaeobacter gallaeciensis and some marine 
algae species such as Emiliania huxleyi [109-111].  Algae provide a carbon and sulfur 
source for P. gallaeciensis in the form of DMSP and in return, the bacteria produce an 
algal growth promoter, phenylacetic acid, as well as a broad-spectrum antibiotic, 
tropodithietic acid (TDA), which suppresses the growth of parasitic bacteria [28, 109-
112].  The bacteria switch from a mutualist to an opportunistic pathogen however, 
when the algae begin to senesce [109, 110].   Under these conditions the algae release 
p-coumaric acid, which triggers the bacteria to produce potent algaecides, 
roseobacticide A and B [109, 110]. 
Phaeobacter inhibens S4Sm, formerly classified as P. gallaeciensis S4Sm 
[107], is a member of the α-Proteobacteria from the Roseobacter clade.  P. inhibens 
S4Sm is a pleomorphic rod with 1-2 flagella on one or both poles and can elongate 
and form rosettes in stationary phase [107].  It is a heterotrophic strict aerobe and 
grows optimally at temperatures between 18 and 30 °C [107].  P. inhibens S4Sm is a 
probiotic organism that can protect eastern oyster (C. virginica) larvae from bacterial 
pathogens [28, 107].  Pretreating oyster larvae with P. inhibens S4Sm significantly 
increases their survival after challenge with either A. crassostreae CV919-312
T
 or V. 
coralliilyticus RE22 (Figure 4) [107].  P. gallaeciensis can also protect cod and turbot 
larvae from V. anguillarum, the causative agent of vibriosis [26, 27]. 
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Figure 4. Effect of preincubation of larval oysters with candidate probiont P. inhibens 
S4Sm at 10
4
 CFU/ml on survival (% ±SD) 24 h after challenge with bacterial 
pathogens A. crassostreae CV919-312
T
 and V. coralliilyticus RE22 at 10
5
 CFU/ml.  
The candidate probionts were introduced 24 h before larvae were challenged.  
Different letters indicate statistical significance among groups (1-way ANOVA, p < 
0.05) [107]. 
 
The probiotic activity of P. inhibens S4Sm can be attributed to at least three 
factors: 1) excellent biofilm forming ability [28]; 2) production of TDA [28]; and 3) 
ability to quench/inhibit the quorum sensing-dependent production of the virulence 
factor protease in V. coralliilyticus RE22 [29].  Toxicology studies using Artemia sp. 
and Caenorhabditis elegans have shown that both P. inhibens as well as purified TDA 
are innocuous for these organisms [30].  P. inhibens S4Sm produces a more robust 
biofilm than the fish pathogen V. anguillarum or the oyster pathogens A. crassostreae 
or V. coralliilyticus (Table 1) [28].  Knockout mutants of P. inhibens S4Sm which 
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were deficient in biofilm formation (exoP) or antibiotic production (clpX) were shown 
to provide significantly less protection to oyster larvae after challenge with V. 
coralliilyticus RE22 compared to wild-type P. inhibens S4Sm, demonstrating the 
importance of these activities for probiotic function (Figure 5) [28].  Additionally, 
TDA knockout mutants of P. gallaeciensis do not protect cod larvae challenged with 
V. anguillarum as well as wild type P. gallaeciensis [26] and do not reduce cell 
densities of V. anguillarum as well as wild type P. gallaeciensis [113].  P. inhibens 
S4Sm has also been shown to produce acyl-homoserine lactones (AHLs) which down-
regulate the virulence factor protease activity in V. coralliilyticus by disrupting the 
quorum-sensing pathway that activates protease transcription of V. coralliilyticus [29]. 
 
Table 1. Quantification of biofilm formation by measuring optical density at 580 nm 
(OD580) of crystal violet dye attached to the cells forming biofilms on glass tubes at 27 
°C under static conditions at 60 h [28]. 
     OD580 
P. inhibens S4Sm  3.89±0.06 
  
A. crassostreae CV919  0.52±0.08
b
 
  
V. anguillarum NB10  0.58±0.02
b
 
  
V. coralliilyticus RE22  0.54±0.02
b
 
 
b
Statistically significant difference (p <0.05) compared to S4Sm. 
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Figure 5. Oyster larvae survival in the presence of P. inhibens strains after challenge 
with V. coralliilyticus RE22. The P. inhibens S4Sm strains (10
4
 CFU/ml) were 
introduced 24 h before larvae were challenged with V. coralliilyticus RE22 (10
5
 
CFU/ml). Oyster larvae survival (% ±SD) was determined 24 h after challenge with 
RE22. Bars marked with an asterisk (*) show significant differences (p <0.05). Error 
bars represent one standard deviation [28]. 
 
TDA is effective against a range of both Gram-positive and Gram-negative 
bacteria [114] and acts as a protonophore, which collapses the proton motive force in 
target cells [115].  It has also been shown that resistance to TDA is hard to select [114] 
and the tdaR3 gene, which is predicted to encode for a γ-glutamyl-cyclotransferase, is 
required for TDA resistance [115].  In the TDA resistance model proposed by Wilson 
et al. [115], TdaR3 facilitates the glutamate-dependent acid-response system by 
converting glutathione to 5-oxo-proline, which is then hydrolyzed to glutamate via a 
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5-oxoprolinase.  This glutamate is then decarboxylated to form γ-aminobutyric acid 
(GABA), which is exchanged by an antiporter for glutamate, resulting in the export of 
1 H
+
 per glutamate [115].  The strong biofilm forming ability combined with 
production of antivirulence compounds (AHLs) and a broad-spectrum antibiotic 
(TDA) which pathogens are unlikely to become resistant to, make P. inhibens S4Sm a 
promising candidate for use as a probiotic to control bacterial diseases in aquaculture 
such as AHPND. 
 
Goals of this study 
The overall goal of this study was to isolate and characterize bacteria 
inhibitory towards the growth of V. parahaemolyticus and determine if they can be 
used to prevent or reduce losses due to the AHPND strains of V. parahaemolyticus in 
aquaculture systems.  AHPND causes significant losses in the shrimp aquaculture 
industry and current strategies to control the disease are not effective [9, 10].  The use 
of probiotics has the potential to control AHPND, but new formulations are needed as 
it has been shown that probiotics which are currently available to shrimp farmers in 
Malaysia are not effective at controlling AHPND [49]. 
The first aim of this investigation was to isolate potential probiotic bacteria 
from the environment which can inhibit the growth of V. parahaemolyticus, quantify 
their biofilm formation, and identify their species.  More than 300 bacterial isolates 
were cultured from a variety of sources and used in a zone of inhibition assay to 
determine if they could inhibit the growth of V. parahaemolyticus on an agar surface.  
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Biofilm formation was then quantified using the crystal violet method.  The 16S rRNA 
gene for each isolate was sequenced for species-level identification. 
The second aim of this study was to determine if any of the candidate probiotic 
organisms can increase the survival of Artemia nauplii challenged with AHPND V. 
parahaemolyticus.  A model system using Artemia nauplii challenged with AHPND V. 
parahaemolyticus PSU5579 was developed and used to test candidate organisms for 
probiotic activity. 
The third aim of this study was to determine if any of the candidate probiotic 
organisms can increase the survival of L. vannamei PLs challenged with AHPND V. 
parahaemolyticus.  An assay using L. vannamei PLs challenged with AHPND V. 
parahaemolyticus PSU5579 was developed and used to test candidate organisms for 
probiotic activity. 
The fourth aim was to obtain the genomic sequence of V. parahaemolyticus 
PSU5579 and Bowmanella denitrificans JL63.  Prior to this research, no whole 
genomic sequences were available for any organisms in the Bowmanella genus and no 
bioactive secondary metabolites produced by members of this genus had been 
identified.  The genomes of these organisms were sequenced and subsequently 
annotated by various software programs.  The genome of V. parahaemolyticus 
PSU5579 was analyzed for potential virulence factors and the genome of B. 
denitrificans JL63 was analyzed for genes responsible for the production of 
compounds which can inhibit the growth of V. parahaemolyticus. 
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Abstract 
Acute hepatopancreatic necrosis disease (AHPND) causes mass mortalities in 
farmed penaeid shrimp and has proven difficult to control using typical disease control 
measures.  The causative agent of AHPND has been identified as Vibrio 
parahaemolyticus strains possessing the 69 kbp plasmid pVPA3-1 containing genes 
homologous with Photorhabdus insect-related (Pir) toxin-like genes (pirA- and pirB-
like).  Probiotics have been used successfully in shrimp aquaculture to control disease 
outbreaks caused by pathogenic Vibrio spp., but there are currently no probiotics 
available that have been proven to control AHPND.  The goal of this study was to 
screen and characterize marine bacterial isolates as potential agents to prevent Artemia 
nauplii and Litopenaeus vannamei post-larvae (PL) mortality by the pathogen V. 
parahaemolyticus.  Twelve candidate probionts were tested in an Artemia sp. model.  
Phaeobacter inhibens was the only candidate probiont tested that could significantly 
increase the survival of Artemia nauplii challenged with AHPND V. parahaemolyticus 
(p<0.001).   Candidate probionts Pseudoalteromonas piscicida, Pseudoalteromonas 
flavipulchra, and Pseudoalteromonas arabiensis caused mortality in Artemia nauplii 
(p<0.001).  Six species of candidate probionts were tested in L. vannamei.  P. inhibens 
was the only candidate probiont tested which was not harmful to L. vannamei PLs and 
significantly increased the survival of PLs challenged with AHPND V. 
parahaemolyticus by 41% (p<0.001). 
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Introduction 
In 2009 an emerging disease now known as acute hepatopancreatic necrosis 
disease (AHPND) began to affect penaeid shrimp farms in southern China [1, 2].  The 
disease has spread to Vietnam, Malaysia, Thailand, and Mexico with global losses 
from AHPND estimated to be more than one billion US dollars annually [2-5].  
AHPND affects both whiteleg shrimp (Litopenaeus vannamei) and black tiger shrimp 
(Penaeus monodon) and can lead to 100 % mortality in affected populations [3].  The 
disease causes serious production losses in affected areas, which negatively impacts 
local employment, social welfare, and international markets [6].  The causative agent 
of AHPND has been identified as Vibrio parahaemolyticus strains possessing the 69 
kbp plasmid pVPA3-1 containing genes homologous with Photorhabdus insect-related 
(Pir) toxin-like genes (pirA- and pirB-like) [2, 7].  AHPND has proven difficult to 
control using typical disease control measures such as water disinfection and antibiotic 
treatment [8, 9]. 
Disease prevention can be challenging for shrimp farmers because most 
farmers do not have resources necessary to treat seawater before it is used to fill their 
ponds [10]. Further, by the time shrimp show signs of AHPND, it is difficult to treat 
as antibiotic treatment has proven unsuccessful in most cases [9] and antibiotic 
treatment will select for antibiotic resistant bacteria.  Additionally, treating water 
sources with chlorine, ozone, or UV before stocking does not provide total sterility 
[8].  Further, disinfection of water perturbs the natural microbial balance, leaving the 
environment open to opportunistic bacteria that survive disinfection, and can actually 
favor the growth of Vibrio species, which grow rapidly after their competitors are 
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removed [11].  Occurrences of overgrowth of pathogenic bacteria such as Vibrio in 
shrimp grow-out ponds can be reduced by minimizing disturbances such as water 
disinfection that can lead to sudden variations in nutrient levels, and by colonizing 
pond water with nonpathogenic bacteria and/or algae [12]. 
Current recommendations to prevent AHPND outbreaks in shrimp farms 
include the use greenwater systems [13] or the application of biocontrol strategies 
such as probiotics [5], phage [14], or Bdellovibrio-and-like organisms (BALOs) [15].  
Studies have shown that probiotics can be used in aquaculture to prevent diseases in a 
variety of farmed species while also improving harvest yields [16-23].  Probiotics 
provide several benefits in aquaculture including improvement of water quality, 
enhancement of nutrition of host species, reduced incidence of diseases, higher 
survival rates, and improved host immune response [16, 18, 24].  Probiotics have been 
used successfully in shrimp aquaculture to control disease outbreaks caused by 
pathogenic Vibrio spp. [16-18, 20, 21] and may have the potential to control AHPND.  
Probiotics provide an alternative to the use of antibiotics in aquaculture, which have 
become increasingly controversial and ineffective due to the emergence of antibiotic 
resistance in bacteria [16, 25-27].  Currently there are no probiotics commercially 
available to shrimp farmers that have proven to be effective at preventing AHPND.  A 
recent study determined that the probiotics which are available to shrimp farmers in 
Malaysia are not effective at controlling AHPND [28]. 
Before potential probiotic organisms can be used in aquaculture, they must be 
tested to confirm that no pathogenic effects can occur in the host.  Artemia spp. have 
been used as a model organism not only for toxicology studies but also to test the 
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effectiveness of probiotics and the role of quorum sensing in pathogenesis [29-36].  
Artemia spp. are useful model organisms because they adapt easily to changes in 
nutrients, salinity, temperature, and oxygen, are easy to culture, are resistant to 
manipulation, have a short life cycle, and are inexpensive [35]. 
In this study, ten newly isolated potential probionts, as well as two oyster 
probionts, Phaeobacter inhibens S4Sm and Bacillus pumilus RI06-95, were identified 
as having in vitro antibiotic activity against an AHPND strain of V. parahaemolyticus.  
These 12 candidate probionts were tested in vivo for their ability to protect Artemia 
nauplii or L. vannamei post-larvae (PL) from AHPND V. parahaemolyticus challenge.  
It was found that P. inhibens S4Sm was the only candidate probiont tested which 
significantly increased the survival of Artemia nauplii challenged with AHPND V. 
parahaemolyticus.  All species of Pseudoalteromonas tested were found to be 
pathogenic to Artemia sp.  P. inhibens S4Sm was also the only candidate probiont 
which was not harmful to L. vannamei PLs and significantly increased the survival of 
PLs challenged with AHPND V. parahaemolyticus. 
 
Materials and Methods 
Bacterial strains and growth conditions 
  Candidate probionts used in this study are listed in Table 1.  All bacteria were 
grown for 24 h at 27 °C with shaking.  All Bacillus strains were grown in 2×LB30IOS 
(20 g/L tryptone, 10 g/L yeast extract, 30 g/L Instant Ocean
®
, pH 7).  P. inhibens 
S4Sm, Bowmanella denitrificans JL63, and all Pseudoalteromonas strains were grown 
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in LB30IOS (10 g/L tryptone, 5 g/L yeast extract, 30 g/L Instant Ocean
®
, pH 7).  V. 
parahaemolyticus strains were grown in LB20 (10 g/L tryptone, 5 g/L yeast extract, 20 
g/L NaCl, pH 8).  Spontaneous streptomycin-resistant mutants were selected by 
passing on increasing concentrations of streptomycin, up to 200 µg/ml.  These strains 
are indicated by “Sm” at the end of their strain name.  All bacterial strains were 
maintained and stored in 25% glycerol stocks at -80 °C. 
 
Isolation of candidate probiotic bacteria 
  Environmental samples, such as seawater or small marine invertebrates, such 
as shrimp, were collected for the isolation of bacteria (Table 1.).  Seawater collected 
from Narragansett Bay, Rhode Island, USA was serially diluted in sterile artificial 
seawater (ASW) (30 g/L Instant Ocean
®
, pH 8, autoclaved) and 100 µl of each 
dilution was spread on YP30IOS agar (5 g/L peptone, 1 g/L yeast extract, 30 g/L 
Instant Ocean
®
, 15 g/L agar, pH 7.5) and incubated at 27 °C for 24-48 h.  Small 
marine invertebrates were blended in sterile ASW in a sterile blender, serially diluted 
in sterile ASW, and 100 µl of each dilution was spread on YP30IOS agar and 
incubated at 27 °C for 24-48 h.  Isolated bacterial colonies were picked from the 
YP30IOS agar and inoculated into LB30IOS and incubated at 27 °C with shaking for 
24-48 h before being used in zone of inhibition assays. 
 
 
 
42 
 
16S rRNA gene sequencing 
  Genomic DNA was isolated using the Bio Basic EZ-10 Spin Column Bacterial 
Genomic DNA Miniprep Kit.  Primers 27F (5’-AGAGTTTGATCCTGGCTCAG-3’) 
and 1525R (5’-AAGGAGGTGWTCCARCC-3’) were used to amplify the 16S rRNA 
gene [37].  Extracted gDNA (1 µl at a concentration of 10-60 ng/µl) was combined 
with 1 µl of each primer (stock solution, 10 µmol), 9.5 µl nuclease-free water, and 
12.5 µl of QIAGEN Taq PCR master mix.  Reaction conditions were 95 °C for 2 min, 
followed by 35 cycles of 94 °C for 15 s, 53 °C for 30 s, and 72 °C for 1.5 min; and a 
final extension at 72 °C for 5 min.  PCR products were sequenced at the University of 
Rhode Island Genomics and Sequencing Center. 
 
Zone of inhibition assay 
  Zones of inhibition were quantified using a modification of a method described 
previously [38].  V. parahaemolyticus PSU5429 was grown for 24 h in LB20, diluted 
10
3
-fold, and 100 µl of this diluted culture was spread on YP30IOS agar.  The 
candidate probionts (10 µl of a 24 h culture) were then spotted on the same plate.  
Plates were incubated at 27 °C for 24-48 h.  Inhibition zones were measured between 
growth of the candidate probiont (edge of spot) and the V. parahaemolyticus lawn 
(edge of lawn).  Each candidate probiont was tested three times. 
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Biofilm assay 
  Biofilm formation was quantified using a modification of the crystal violet 
staining method [39].  Bacteria were grown for 24 h before being diluted 10
3
-fold into 
200 µl of YP30IOS in a polystyrene 96-well plate which was then incubated at 27 °C 
for 24 h under static conditions.  Biofilms in the wells were washed with ASW twice, 
stained with 0.2% crystal violet for 20 min, washed twice with ASW, and biofilm-
bound crystal violet was eluted with 95% ethanol for 30 min before being measured at 
OD580.  Each candidate probiont was tested in three wells per experiment and each 
experiment was repeated twice. 
 
Characterization of V. parahaemolyticus strains using duplex PCR for the 
detection of pirA- and pirB-like genes 
  Ten strains of V. parahaemolyticus isolated from shrimp farms located in 
Pattani and Songkla provinces, southern Thailand during an AHPND outbreak were 
screened for pirA- and pirB-like genes.  These V. parahaemolyticus strains were gifted 
to us from Wenjing Zhao at the Mekalanos Lab, Harvard Medical School.  Genomic 
DNA was isolated using the Bio Basic EZ-10 Spin Column Bacterial Genomic DNA 
Miniprep Kit.  Primers VpPirA-284F (5’-TGACTATTCTCACGATTGGACTGR-3’), 
VpPirA-284R (5’-CACGACTAGCGCCATTGTTA-3’), VpPirB-392F (5’-
TGATGAAGTGATGGGTGCTC-3’), and VpPirB-392R (5’-
TGTAAGCGCCGTTTAACTCA-3’) were used to amplify the pirA- and pirB-like 
genes [2].  1 µl of extracted gDNA (10-60 ng/µl) was combined with 1 µl of each 
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primer (10 µmol), 7.5 µl nuclease-free water, and 12.5 µl of QIAGEN Taq PCR 
master mix.  Reaction conditions were 94 °C for 3 min, followed by 35 cycles of 94 
°C for 30 s, 60 °C for 30 s, and 72 °C for 30 s; and a final extension at 72 °C for 7 
min.  PCR products were separated on a 2% agarose gel containing ethidium bromide 
(0.4 µg/ml) and visualized on a UV transilluminator.  Presence of pirA-like is 
indicated by a band at 284 bp, while presence of pirB-like is indicated by a band at 
392 bp. 
 
Artemia challenge 
  Artemia cysts (0.075 g) were hatched in an inverted 60 ml syringe, covered 
with perforated plastic wrap, containing 60 ml HEPPS-buffered (10 mM, pH 8.2) 
sterile ASW at 28 °C for 24 h with constant aeration and fluorescent light.  To 
maintain pH and maximize Artemia hatching rate, an increased buffer capacity is 
required to avoid a drop in the pH due to the acid produced by cysts during hatching 
[40].  Hatched nauplii (2 ml, containing approximately 400 nauplii) were transferred 
to 50 ml centrifuge tubes containing 26.3 ml HEPPS-buffered (10 mM, pH 8.2) ASW.  
Nauplii were fed autoclaved Escherichia coli K-12 cells at a final concentration of 10
7
 
cells/ml during hatching and every 24 h.  Candidate probionts were washed twice in 
sterile ASW by centrifugation at 6,000 × g for ten minutes at 4 °C.  Nauplii were 
treated with candidate probionts after hatching and every 24 h.  The centrifuge tubes 
were placed on a rotator set to 4 rpm at 30 °C.  After incubation for 24 h, 1.6 ml 
YP30IOS was added to each tube and nauplii were challenged with 1×10
5
 CFU/ml 
washed V. parahaemolyticus cells.  V. parahaemolyticus cells were washed twice in 
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sterile ASW by centrifugation at 5,000 × g for five minutes at room temperature.  To 
count nauplii, the tubes were inverted five times to mix the nauplii suspension, 1 ml of 
the nauplii suspension was transferred into each well of a tri-well petri dish containing 
5 ml of ASW with 0.05% agar (to slow nauplii movement during counting), and 
nauplii were viewed under a dissecting microscope.  Nauplii were counted at 24 h and 
72 h to quantify survival.  Nauplii which showed any signs of movement were counted 
as alive.  Each treatment was tested in three tubes and was repeated twice.  Water in 
each tube was not changed during the experiment. 
 
Whiteleg shrimp (Litopenaeus vannamei) post-larvae challenge 
  Litopenaeus vannamei PLs were purchased from Miami-Aquaculture (Boynton 
Beach, Florida, USA) and maintained at room temperature in ASW in a 20 L 
aquarium tank with filtration (Hagen
®
 AquaClear
®
 50 power filter, Mansfield, MA) 
and weekly water changes.  PLs (approximately 10 mm – 20 mm in length) were fed 
Hagen
®
 Fluval
®
 (Mansfield, MA) Shrimp Granules daily.  Six PLs were transferred to 
250 ml bottles with 200 ml ASW containing 200 µg/ml streptomycin and provided 
aeration through a sterile air stone.  Streptomycin-resistant candidate probionts were 
washed twice in sterile ASW by centrifugation at 6,000 × g for ten minutes at 4 °C.  
PLs were treated with probiotics at 1×10
6
 CFU/ml at the beginning of the experiment 
and every 24 h.  After a 24 h pretreatment period, PLs were challenged with 1×10
6
 
CFU/ml washed streptomycin-resistant V. parahaemolyticus PSU5579Sm cells. V. 
parahaemolyticus PSU5579Sm was washed twice in sterile ASW by centrifugation at 
5,000 × g for five minutes at room temperature.  PLs were incubated at 30 °C and 
46 
 
survival was quantified 48 h post-challenge.  Each treatment was tested in three bottles 
and the experiment was repeated twice.  Water in each bottle was not changed during 
the experiment. 
 
Statistical analysis 
Statistical data analysis was performed using the Student’s t-test. Data with 
p<0.05 was considered to be statistically significant. 
 
Results 
Isolation of candidate probiotic bacteria and 16S sequencing 
More than 300 bacterial isolates were screened for antibiotic activity against V. 
parahaemolyticus PSU5429 by zone of inhibition (ZOI) assay.  A total of 30 isolates 
were found to inhibit the growth of V. parahaemolyticus PSU5429.  The 16S rRNA 
genes of these isolates were sequenced to identify their species, and these data 
combined with the ZOI and biofilm data were analyzed to rule out strains that were 
isolated more than once.  This analysis revealed that of the 30 original isolates, 10 
were unique strains (Table 1), while the remaining 20 isolates were duplicates.  Two 
oyster probiotic organisms, P. inhibens S4Sm and B. pumilus RI06-95, previously 
identified by Karim et al. [41], were also tested by ZOI and found to inhibit the growth 
of V. parahaemolyticus PSU5429.  B. pumilus HR1 was gifted to us by Hilary Ranson 
at the Rowley lab, University of Rhode Island. 
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Table 1. Candidate probiotic organisms that produce a zone of inhibition against V. 
parahaemolyticus PSU5429. 
Candidate Probiont Source Location of collection Reference 
Phaeobacter inhibens S4Sm Oyster shell Rhode Island Karim et al. [41] 
Bacillus pumilus RI06-95 Marine sponge Narrow River, RI Karim et al. [41] 
Pseudoalteromonas 
piscicida GR1 
Seawater Galilee, Narragansett, RI This study 
Pseudoalteromonas 
flavipulchra GR4 
Seawater Galilee, Narragansett, RI This study 
Pseudoalteromonas 
flavipulchra JL1 
Seawater Upper Pond, South Kingstown, 
RI 
This study 
Pseudoalteromonas 
piscicida JL12 
Seawater Upper Pond, South Kingstown, 
RI 
This study 
Pseudoalteromonas 
piscicida JL15 
Brine shrimp Critter Hut, Wakefield, RI This study 
Pseudoalteromonas 
flavipulchra JL18 
Brine shrimp Critter Hut, Wakefield, RI This study 
Pseudoalteromonas 
arabiensis JL29 
Brine shrimp Critter Hut, Wakefield, RI This study 
Bowmanella denitrificans 
JL63 
Whiteleg 
shrimp 
SKy8 Shrimp Farm, Stoughton, 
MA 
This study 
Bacillus pumilus JL70 Gulf shrimp 
hindgut 
Gulf of Mexico This study 
Bacillus pumilus HR1 Lobster shell Narragansett Bay, RI This study 
 
 
Zone of inhibition assay 
Zones of inhibition (ZOI) produced by candidate probionts against V. 
parahaemolyticus PSU5429 were quantified to evaluate each organism’s ability to 
inhibit V. parahaemolyticus growth on an agar surface.  ZOIs are areas around the 
candidate probiont spot where V. parahaemolyticus was plated, but was not able to 
grow due to the presence of growth-inhibiting compound(s) secreted by the candidate 
probiont.  Of the 12 candidate probionts, Pseudoalteromonas flavipulchra JL1 and 
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GR4 and  Pseudoalteromonas piscicida JL15 produced the largest ZOIs (6.4 mm, 4.6 
mm, and 5.9 mm, respectively) (Figure 1).  P. inhibens S4Sm, Ps. piscicida GR1 and 
JL12, and Ps. flavipulchra JL18 produced moderate ZOIs (1.5 mm, 1.7 mm, 2.2 mm, 
and 1.2 mm, respectively) (Figure 1).  Pseudoalteromonas arabiensis JL29, B. 
denitrificans JL63, and B. pumilus RI06-95, JL70, and HR1 produced the smallest 
ZOIs (0.1 mm, 0.3 mm, 0.4 mm, 0.7 mm, and 0.6 mm, respectively) (Figure 1). 
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Figure 1. Zones of inhibition produced by candidate probionts against V. 
parahaemolyticus PSU5429.  100 µl of a 10
3
-fold diluted stationary phase V. 
parahaemolyticus culture was spread on YP30 agar and 10 µl of a stationary phase 
culture of each candidate probiont was spotted over the V. parahaemolyticus lawn.  
Plates were incubated at 27 °C for 24-48 h.  Inhibition zones were measured between 
growth of the candidate probiont and the V. parahaemolyticus lawn.  Representative of 
three independent experiments.  Error bars equal one standard deviation. 
 
Biofilm assay 
 The biofilm forming ability of each candidate probiont, as well as V. 
parahaemolyticus PSU5579, was quantified to determine if any of the candidate 
probionts can form stronger biofilms than V. parahaemolyticus.  Of the 12 candidate 
probionts, P. inhibens S4Sm, B. pumilus RI06-95, Ps. piscicida GR1, Ps. flavipulchra 
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JL1, Ps. piscicida JL12, and Ps. flavipulchra JL18 produced the strongest biofilms 
(OD580 = 3.7, 3.3, 3.2, 3.2, 3.0, and 3.4 respectively) (Figure 2).  Ps. flavipulchra GR4, 
Ps. piscicida JL15, B. denitrificans JL63, and B. pumilus JL70 produced moderate 
biofilms (OD580 = 2.3, 2.1, 2.4, and 2.6 respectively) while Ps. arabiensis JL29 and B. 
pumilus HR1 were the weakest biofilm formers (OD580 = 1.3 and 0.8 respectively) 
(Figure 2).  V. parahaemolyticus PSU5579 produced a weak biofilm (OD580 = 0.7) 
(Figure 2).  The only candidate probiont that did not produce a significantly stronger 
biofilm than V. parahaemolyticus PSU5579 was B. pumilus HR1 (p=0.565) (Figure 2).  
The eleven other candidate probionts all produced significantly stronger biofilms than 
V. parahaemolyticus PSU5579 (p<0.006) (Figure 2). 
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Figure 2. Biofilm formation quantified by the crystal violet method.  Cultures were 
grown, as described in the Methods, in 96-well plates for 24 hours at 27 °C.  Biofilms 
in the wells were washed with ASW, stained with 0.2% crystal violet, washed again, 
and biofilm-bound crystal violet was eluted with 95% ethanol before the optical 
density was measured at 580 nm (OD580).   Representative of three independent 
experiments with three technical replicates per experiment.  Error bars equal one 
standard deviation.  * indicates statistically significant difference from V. 
parahaemolyticus PSU5579 (t-test, p<0.05). 
 
Duplex PCR for the detection of pirA- and pirB-like genes 
 In order to confirm that the putative AHPND strains of V. parahaemolyticus 
contained the genes necessary to cause this shrimp disease, ten strains of V. 
parahaemolyticus isolated from shrimp farms located in Pattani and Songkla 
provinces, southern Thailand during an AHPND disease outbreak were screened for 
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pirA- and pirB-like genes by duplex PCR.  Six of these strains (PSU5429, PSU5495, 
PSU5501, PSU5507, PSU5520, and PSU5579) possess both pirA- and pirB-like genes 
(Figure 3).  Three of these strains (PSU5580, PSU5585, and PSU5599) possess only 
pirA-like and one strain (PSU5587) lacks both pirA- and pirB-like genes (Figure 3).  
Strains which possess both pirA- and pirB-like genes have the potential to cause 
AHPND.  All six strains possessing both pirA- and pirB-like genes were used in a 
preliminary experiment to challenge Artemia nauplii.  Of the six strains tested, V. 
parahaemolyticus PSU5579 induced the highest mortality rate in Artemia nauplii 
(Figure S1) and was chosen as the strain to be used in future experiments.  For this 
preliminary experiment, Artemia were not fed during hatching and were challenged 
with V. parahaemolyticus strains immediately after hatching without the 24 h 
pretreatment period used in other experiments.  This protocol was later modified (as 
described in the Materials and Methods) to allow for a 24 h pretreatment period. 
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Figure 3. Duplex PCR detection of pirA- and pirB-like genes found on the pVPA3-1 
plasmid. PCR amplification was performed using primers VpPirA-284F/R and 
VpPirB-392F/R and was viewed on a 2% agarose gel containing ethidium bromide 
(0.4 µg/ml) as described by Han et al. [2].  Presence of a pirA-like amplicon is 
indicated by a band at 284 bp, while presence of a pirB-like amplicon is indicated by a 
band at 392 bp. 
 
Artemia challenge studies 
To determine if any of the candidate probiotic organisms have the potential to 
prevent AHPND, an assay was developed to test if candidate probionts could protect 
Artemia nauplii from AHPND V. parahaemolyticus challenge.  This assay also served 
as a test to determine if any of the candidate probionts can be harmful to crustaceans, 
such as Artemia sp., under certain conditions.  For this assay, the addition of 1.6 ml 
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YP30IOS allowed for V. parahaemolyticus PSU5579 to consistently induce a 53% - 
71% mortality rate in Artemia nauplii when applied at 10
5
 CFU/ml 24 h after hatching 
(Figure S2).  When V. parahaemolyticus PSU5579 was applied at 10
4
 CFU/ml 24 h 
after hatching, the mortality rate was lower (39% - 49%) (Figure S2).  The higher 
mortality rate induced by V. parahaemolyticus PSU5579 when applied at 10
5
 CFU/ml 
provides a range of survival between the challenged and unchallenged controls where 
a level of protection provided by probiotic organisms can be detected, which is why 
this concentration was used for these experiments.  Without the addition of YP30IOS, 
challenging Artemia nauplii 24 h after hatching with V. parahaemolyticus PSU5579 at 
10
6
 or 10
7
 CFU/ml only induced 0% or 28% mortality, respectively (Figure S3). 
Twelve candidate probiotic organisms were tested for their potential ability to 
kill Artemia nauplii, as well as their ability to protect nauplii from challenge with V. 
parahaemolyticus PSU5579.  Artemia nauplii pretreated with 10
6
 CFU/ml P. inhibens 
S4Sm for 24 h exhibited a statistically significant 1.8-fold increase in survival (70% 
survival) when challenged with V. parahaemolyticus PSU5579 (p<0.001) compared to 
the Artemia challenge control (38% survival) (Figure 4).  Artemia nauplii pretreated 
with P. inhibens S4Sm at 10
6
 CFU/ml had 32% higher survival after challenge with V. 
parahaemolyticus PSU5579 than those pretreated with P. inhibens S4Sm at 10
5
 
CFU/ml (Figure S4).  None of the other eleven probiont candidate isolates were able 
to protect Artemia nauplii from infection and death when challenged with V. 
parahaemolyticus PSU5579 (Figures 5 and 6).  Artemia nauplii treated with P. 
inhibens S4Sm at 10
6
 CFU/ml daily for 72 h (probiotic control) exhibited a 17.6% 
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decline in survival (to 75%) compared to the untreated control (91%) (p=0.001) 
(Figure 4). 
Candidate probionts B. pumilus strains RI06-95, JL70, and HR1 tested at 10
4
, 
10
5
, and 10
6
 CFU/ml did not have any significant effect on the survival of Artemia 
nauplii challenged with V. parahaemolyticus PSU5579 (p>0.094) (Figure 5).  Survival 
of Artemia challenged with V. parahaemolyticus PSU5579 averaged 33%, while 
survival of Artemia treated with the various B. pumilus strains and then challenged 
ranged from 32-42%.   In contrast, Ps. piscicida strains GR1, JL12, and JL15, Ps. 
flavipulchra strains GR4, JL1, and JL18, Ps. arabiensis JL29, and B. denitrificans 
JL63 tested at 10
4
 CFU/ml all significantly decreased (0% vs. 37%) the survival of 
Artemia nauplii challenged with V. parahaemolyticus PSU5579 (p<0.001) (Figure 6). 
In all cases, the Artemia treated with these candidate probionts and then challenged 
with PSU5579 showed 100% mortality. Further, Artemia treated only with the 
candidate probionts Ps. flavipulchra JL1, Ps. piscicida JL15, and Ps. arabiensis JL29 
at 10
5
 CFU/ml daily (with no V. parahaemolyticus challenge) exhibited significantly 
decreased survival (p<0.001) (with only 0%, 5%, 4% survival, respectively) (Figure 
7). The untreated control Artemia exhibited 85% survival.  Treating Artemia nauplii 
daily with B. denitrificans JL63 at 10
5
 CFU/ml for 72 h reduced survival to 62%, but 
this decline (compared to the control) was not significant (p=0.063) (Figure 7). 
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Figure 4. Effect of preincubation of Artemia nauplii with P. inhibens S4Sm at 10
6
 
CFU/ml for 24 h on survival 48 h after challenge with V. parahaemolyticus PSU5579 
at 10
5
 CFU/ml.  P. inhibens S4Sm was added at the start of the experiment and every 
24 h.  Representative of three independent experiments with three technical replicates 
per experiment.  Error bars equal one standard deviation.  Different letters indicate 
statistical significance among groups (t-test, p<0.05). 
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Figure 5. Effect of preincubation of Artemia nauplii with B. pumilus RI06-95, JL70, 
and HR1 at 10
4
, 10
5
, and 10
6
 CFU/ml for 24 h on survival 48 h after challenge with V. 
parahaemolyticus PSU5579 at 10
5
 CFU/ml.  Candidate probionts were added at the 
start of the experiment and every 24 h.  Representative of three independent 
experiments with three technical replicates per experiment.  Error bars equal one 
standard deviation. * indicates statistically significant difference from the V. 
parahaemolyticus PSU5579 treatment (t-test, p<0.05). 
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Figure 6. Effect of preincubation of Artemia nauplii with Ps. piscicida GR1, JL12, 
and JL15, Ps. flavipulchra GR4, JL1, and JL18, Ps. arabiensis JL29, and B. 
denitrificans JL63 at 10
4
 CFU/ml for 24 h on survival 48 h after challenge with V. 
parahaemolyticus PSU5579 at 10
5
 CFU/ml.  Candidate probionts were added at the 
start of the experiment and every 24 h.  Representative of three independent 
experiments with three technical replicates per experiment.  Error bars equal one 
standard deviation. * indicates statistically significant difference from the V. 
parahaemolyticus PSU5579 treatment (t-test, p<0.05). 
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Figure 7. Survival of Artemia nauplii treated with Ps. flavipulchra JL1, Ps. piscicida 
JL15, Ps. arabiensis JL29, and B. denitrificans JL63 at 10
5
 CFU/ml daily for 72 h.  
Representative of three independent experiments with three technical replicates per 
experiment.  Error bars equal one standard deviation. * indicates statistically 
significant difference from the Control (t-test, p<0.05). 
 
Whiteleg shrimp (Litopenaeus vannamei) post-larvae challenge 
 An assay was developed to test if any of the candidate probionts could protect 
L. vannamei PLs from AHPND V. parahaemolyticus challenge.  An initial experiment 
determined that V. parahaemolyticus PSU5579Sm induces a high mortality rate (67%) 
in L. vannamei PLs when applied at 10
6
 CFU/ml at the start of the experiment; 
however, when PLs were incubated for 24 h prior to the addition of V. 
parahaemolyticus, the mortality rate was reduced to 33% (Figure S5).  This may be 
due to the growth of commensal bacteria from the shrimp during the 24 h 
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preincubation period, which then compete with V. parahaemolyticus for available 
nutrients.  This 24 h preincubation period is important because probiotics usually 
require a pretreatment period to effectively protect animals from pathogen challenge 
[42, 43].  This issue was resolved through the addition of 200 µg/ml streptomycin to 
the PL water at the start of the experiment which allowed for a 24 h preincubation 
period without a reduced V. parahaemolyticus-induced mortality rate when applied at 
10
6
 CFU/ml (67%) (Figure S5).  Challenging L. vannamei PLs with 10
5
 CFU/ml V. 
parahaemolyticus PSU5579Sm after a 24 h preincubation period with streptomycin 
only induced a 5% mortality rate (Figure S5). 
In order to determine if any of the candidate probionts are harmful to shrimp, 
L. vannamei PLs were treated with each species of candidate probiont at 10
6
 CFU/ml 
daily for 72 h.  PLs treated with P. inhibens S4Sm, Ps. piscicida JL15Sm, Ps. 
arabiensis JL29Sm, B. denitrificans JL63Sm, or B. pumilus RI06-95Sm daily for 72 h 
did not exhibit any significantly decline in survival that ranged from 92-98% when 
compared to untreated control PLs with 97% survival (p>0.187) (Figure 8).  The only 
species that significantly decreased the survival of L. vannamei PLs was Ps. 
flavipulchra JL1Sm with 83% survival compared to 97% in the untreated control 
(p=0.008) (Figure 8). 
In an effort to determine if any of the candidate probionts can protect L. 
vannamei PLs from V. parahaemolyticus challenge, PLs were pretreated with 
candidate probionts at 10
6
 CFU/ml for 24 h before V. parahaemolyticus PSU5579Sm 
challenge and, as described previously, the candidate probionts were also added every 
24 h.  Both P. inhibens S4Sm and Ps. flavipulchra JL1Sm significantly increased the 
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survival of L. vannamei PLs challenged with V. parahaemolyticus PSU5579Sm to 
87%, 80%, respectively (p<0.001).  Infection control PLs exhibited only 46% survival 
(Figure 9).  As seen with the Artemia challenge experiments, treatments with P. 
inhibens S4Sm increased survival by nearly 2-fold.  Ps. piscicida JL15Sm, Ps. 
arabiensis JL29Sm, B. denitrificans JL63Sm, and B. pumilus RI06-95Sm did not 
significantly affect the survival of L. vannamei PLs challenged with V. 
parahaemolyticus PSU5579Sm with survival of PLs ranging from 35-54% (p>0.051) 
(Figure 9).  These results indicate that P. inhibens S4Sm is the only candidate 
probiotic organism tested which is not harmful to L. vannamei PLs and can 
significantly increase the survival of PLs challenged with AHPND V. 
parahaemolyticus. 
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Figure 8. Survival of L. vannamei PLs treated with P. inhibens S4Sm, Ps. 
flavipulchra JL1Sm, Ps. piscicida JL15Sm, Ps. arabiensis JL29Sm, B. denitrificans 
JL63Sm, and B. pumilus RI06-95Sm at 10
6
 CFU/ml daily for 72 h.  Representative of 
three independent experiments with three technical replicates per experiment.  Error 
bars equal one standard deviation. * indicates statistically significant difference from 
the Control (t-test, p<0.05). 
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Figure 9. Effect of preincubation of L. vannamei PLs with P. inhibens S4Sm, Ps. 
flavipulchra JL1Sm, Ps. piscicida JL15Sm, Ps. arabiensis JL29Sm, B. denitrificans 
JL63Sm, and B. pumilus RI06-95Sm at 10
6
 CFU/ml for 24 h on survival 48 h after 
challenge with V. parahaemolyticus PSU5579Sm at 10
6
 CFU/ml.  Candidate probionts 
were added at the start of the experiment and every 24 h.  Representative of three 
independent experiments with three technical replicates per experiment.  Error bars 
equal one standard deviation. * indicates statistically significant difference from the V. 
parahaemolyticus PSU5579Sm treatment (t-test, p<0.05). 
 
Discussion 
 
The present study aimed to determine if probiotic bacteria can decrease the 
mortality rate of L. vannamei challenged with AHPND V. parahaemolyticus and if 
Artemia spp. can be used as a model organism to evaluate the potential of candidate 
probionts to control AHPND.  Candidate probionts were selected by screening for 
production of compounds inhibitory toward the growth of V. parahaemolyticus.  This 
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characteristic is an important property for probiotics used for disease control [38, 44], 
and is commonly used as a primary test in selecting candidate probionts, but does not 
necessarily guarantee that candidate probionts will be effective at protecting live host 
organisms such as shrimp [45].  Candidate probionts were characterized and tested for 
their ability to protect both L. vannamei and Artemia sp. from AHPND V. 
parahaemolyticus challenge.  This study identified P. inhibens S4Sm as a bacterial 
candidate, which has the potential to be used as a probiotic for control of AHPND in 
penaeid shrimp aquaculture.  This study also showed that Artemia sp. can be used to 
identify probionts that protect L. vannamei from AHPND V. parahaemolyticus 
challenge.  Under the conditions used in this study, Artemia sp. were also shown to 
have a higher sensitivity than L. vannamei to organisms which are harmful to 
crustaceans and, therefore, can be used to identify organisms that should not be used 
in shrimp aquaculture. 
Twelve bacterial strains were selected as candidate probionts for control of 
AHPND because of their antagonistic properties against V. parahaemolyticus.  Two of 
these strains, P. inhibens S4Sm and B. pumilus RI06-95, were oyster probionts 
previously identified by Karim et al. [41].  The other ten strains were isolated during 
this study based on their ability to inhibit the growth of V. parahaemolyticus and were 
identified by 16S rRNA genes sequencing.  The production of antimicrobial 
compounds by these organisms, as determined by ZOI assay, suppresses the growth of 
V. parahaemolyticus, allowing them to outcompete V. parahaemolyticus for nutrients 
and energy sources.  Probiotics with known antagonistic activity have been shown to 
decrease the concentration of Vibrio spp. in black tiger shrimp (P. monodon) rearing 
65 
 
water [46, 47].  Antagonistic probionts have also been shown to inhibit the 
colonization of P. monodon by V. harveyi through competitive exclusion [48]. 
The biofilm forming ability of the twelve candidate probionts as well as V. 
parahaemolyticus PSU5579 was quantified by the crystal violet method using 
polystyrene 96-well plates.  Biofilm formation is an important characteristic for 
probiotic activity because competition for attachment sites within the host is likely to 
serve as the first barrier of defense against invading pathogenic bacteria [16, 38, 44].  
Eleven of the twelve candidate probionts produced significantly stronger biofilms than 
V. parahaemolyticus PSU5579 under the conditions tested (p<0.006).  The only 
candidate probiont that did not produce a significantly stronger biofilm than V. 
parahaemolyticus PSU5579 was B. pumilus HR1 (p=0.565).  The biofilm assay used 
in this study provides insight into the biofilm forming ability of the organisms tested, 
but is not comprehensive and may not be predictive of how well organisms will be 
able to colonize a host.  Some of the organisms tested may form stronger biofilms on a 
biotic surface than on an abiotic surface, and the biofilm forming ability of these 
organisms may be underestimated using this assay.  However, other organisms may 
form strong biofilms on a variety of surfaces. For example, P. inhibens S4Sm, which 
formed the strongest biofilm on polystyrene of any of the organisms tested in this 
study, has also been shown to form a strong biofilm on borosilicate glass [38].  Zhao 
et al. [38] made an exoP-knockout mutant of P. inhibens S4Sm to study the 
contribution of biofilm forming ability to the probiotic activity of this organism.  The 
P. inhibens S4Sm exoP mutant had 60% reduced biofilm forming ability and oyster 
larvae pretreated with this mutant before Vibrio coralliilyticus challenge had 30% 
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lower survival than larvae pretreated with wild-type P. inhibens S4Sm, indicating that 
biofilm formation is important for the probiotic activity of P. inhibens S4Sm [38]. 
All twelve candidate probionts demonstrated antagonistic activity against V. 
parahaemolyticus on an agar surface and eleven of the twelve candidate probionts also 
form stronger biofilms than V. parahaemolyticus on a polystyrene surface.  Organisms 
with both of these characteristics may be able to competitively exclude the pathogen 
from colonizing the host and the surrounding environment, thereby limiting the 
proliferation of the pathogen and reducing the likelihood of disease.  Attachment to 
the host and production of antimicrobial compounds are critical factors for the ability 
of lactic acid bacteria to exclude pathogens in both humans [49, 50] and fish [51].  
Verschuere et al. [31] quantified the colonization of Artemia nauplii by nine candidate 
probionts as well as the ability of these organisms to protect Artemia nauplii from 
Vibrio proteolyticus challenge and observed a correlation between colonization 
potential and the protective ability of the candidate probionts [31].  All twelve 
candidate probionts used in this study showed promising results in vitro; however, 
these results were not predictive of their effectiveness in vivo, possibly due to toxicity 
to the host or other undetermined factors. 
Artemia spp. are an advantageous model organism to test the effectiveness of 
probiotics at reducing pathogen-induced mortality [31, 34, 36].  Verschuere et al. [31] 
found several probionts that provide total protection to Artemia nauplii from V. 
proteolyticus.  Pretreatment of Artemia nauplii with yeast (Saccharomyces boulardii) 
also provides total protection from Vibrio harveyi challenge [36].  Bacillus 
licheniformis and Pseudomonas aeruginosa have also been shown to provide nearly 
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maximum survival (78%) to Artemia nauplii from non-AHPND V. parahaemolyticus 
[34].  This study is the first to test candidate probionts in an AHPND V. 
parahaemolyticus-challenged Artemia sp. model. 
An AHPND strain of V. parahaemolyticus was identified which caused rapid 
mortalities in both Artemia nauplii and L. vannamei PLs.  Animal models using 
Artemia nauplii and L. vannamei PLs challenged with V. parahaemolyticus PSU5579 
were optimized to produce high survival rates (83% – 97%) in unchallenged controls 
and significantly decreased survival rates (33% – 46%) in AHPND V. 
parahaemolyticus-challenged controls (p<0.001).  It is important for experiments 
testing the effect of probiotic treatment on pathogen-challenged animals to have 
healthy animals and a significant pathogen-induced mortality rate in order for a level 
of probiotic protection to be detectable [52]. 
Pretreatment of Artemia nauplii with the twelve candidate probionts before V. 
parahaemolyticus PSU5579 challenge revealed that P. inhibens S4Sm was the only 
candidate probiont that significantly increased Artemia nauplii survival.  None of the 
other eleven probiont candidates were able to protect Artemia from V. 
parahaemolyticus PSU5579 under the conditions tested.   It was observed that Artemia 
nauplii treated with P. inhibens S4Sm at 10
6
 CFU/ml daily for 72 h had reduced 
survival (75%) compared to the untreated control (91%).  It should be noted however, 
that of the candidate probionts tested in this model as probiotic controls, P. inhibens 
S4Sm produced the smallest decline in Artemia nauplii survival.  P. inhibens S4Sm is 
a strict aerobe [53] and may have depleted the oxygen level in the sealed tubes when 
applied daily at 10
6
 CFU/ml.  Neu et al. [29] found that P. inhibens is innocuous to 
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Artemia sp. however.  Neu et al. [29] treated Artemia nauplii with 10
7
 CFU/ml P. 
inhibens only once and 100 ml of the nauplii solution was incubated in 250 ml bottles 
with shaking at 90-100 rpm at 25 °C for 48 h.  The decline in survival of Artemia 
nauplii treated with P. inhibens observed in this study but not observed by Neu et al. 
[29] may be due to any one or combination of the following factors: the addition of 
YP30IOS to the nauplii solution, the additional 24 h of incubation, or the sealed tubes 
used in this study. 
Candidate probionts B. pumilus strains RI06-95, JL70, and HR1 were tested at 
10
4
 – 106 CFU/ml, but did not significantly affect the survival of Artemia nauplii 
challenged with V. parahaemolyticus PSU5579 at 10
5
 CFU/ml (p>0.094).  It was not 
determined if B. pumilus strains could protect Artemia nauplii from lower 
concentrations of V. parahaemolyticus PSU5579.  Although B. pumilus did not have a 
significant effect on the survival Artemia nauplii challenged with AHPND V. 
parahaemolyticus in this study, there still remains the possibility that B. pumilus may 
have an effect if applied to L. vannamei PLs in an aquaculture setting where the 
concentration of AHPND V. parahaemolyticus may be lower than the concentration 
used in this study. 
The remaining candidate probionts, Ps. piscicida strains GR1, JL12, and JL15, 
Ps. flavipulchra strains GR4, JL1, and JL18, Ps. arabiensis JL29, and B. denitrificans 
JL63 when applied at 10
4
 CFU/ml all significantly decreased the survival of Artemia 
nauplii challenged with V. parahaemolyticus PSU5579 (p<0.001).  In all cases, the 
Artemia nauplii treated with these candidate probionts and then challenged with V. 
parahaemolyticus PSU5579 showed 100% mortality.  Artemia treated only with B. 
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denitrificans JL63 daily at 10
5
 CFU/ml reduced survival to 62%, but not significantly 
(p=0.063).  Additionally, Artemia treated only with candidate probionts Ps. 
flavipulchra JL1, Ps. piscicida JL15, and Ps. arabiensis JL29 at 10
5
 CFU/ml daily 
(with no V. parahaemolyticus challenge) exhibited 95% mortality.  All three species of 
Pseudoalteromonas when applied at 10
5
 CFU/ml daily for 72 h induced a higher 
mortality rate in Artemia nauplii than V. parahaemolyticus PSU5579 when applied 
once at 10
5
 CFU/ml.  Results similar to these were shown by Neu et al. [29] who 
determined that Ps. piscicida and Pseudoalteromonas rubra are lethal to Artemia 
nauplii when applied at 10
7
 CFU/ml and induced 95-99% mortality in 48 h. 
A L. vannamei challenge assay was developed to test if any of the candidate 
probionts could protect L. vannamei PLs from AHPND V. parahaemolyticus.  This 
assay involved a 24 h probiotic pretreatment period, which is usually required for 
probiotics to effectively protect animals from pathogen challenge [42, 43].  This 24 h 
pretreatment period allows the probionts to colonize the host and begin producing 
antimicrobial compounds before the pathogen can take hold.  During this period, the 
probiont cells may begin to divide and reach a higher density, allowing them to 
compete with fast growing pathogens such as V. parahaemolyticus, which has been 
shown to have a generation time as short as 12 minutes [54].  For example, the oyster 
probiont P. inhibens S4Sm (generation time = 1.9 h [41]) can inhibit the oyster 
pathogen V. coralliilyticus RE22 from colonizing glass coverslips, but only when P. 
inhibens S4Sm is allowed to precolonize the coverslip for 24 h prior to the 
introduction of the pathogen [38]. 
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For the L. vannamei challenge assay an initial experiment determined that a 24 
h preincubation period prior to 10
6
 CFU/ml V. parahaemolyticus challenge reduced V. 
parahaemolyticus-induced L. vannamei mortality from 67%, when L. vannamei were 
challenged at 0 h, to 33% even without the addition of candidate probionts.  This assay 
uses a much higher PL density than that of even super-intensive shrimp farming 
practices which use a maximum density of 7 PLs per 10 L [55].  Due to this high PL 
density, commensal bacteria from the shrimp likely grew to a high density during the 
24 h preincubation period.  These commensal bacteria then compete with V. 
parahaemolyticus for available nutrients, which may explain why V. 
parahaemolyticus-induced L. vannamei mortality was reduced.  To inhibit the growth 
of commensal bacteria from the PLs, streptomycin (200 µg/ml) was added to the 
shrimp culture water.  The addition of streptomycin restored V. parahaemolyticus-
induced L. vannamei mortality to 67% when applied at 10
6
 CFU/ml (Figure S5).  A 
similar approach using streptomycin treatment is used in mouse models to allow both 
pathogenic and nonpathogenic bacteria to colonize the gastrointestinal tract [56-59].  
Streptomycin treatment renders mice highly susceptible to enteric pathogens due to the 
elimination of commensal facultative intestinal bacteria [59].  This study showed that 
streptomycin treatment has the same effect on L. vannamei by increasing their 
susceptibility to AHPND V. parahaemolyticus. 
 Representatives of each species of candidate probiont were tested to determine 
if they were harmful to L. vannamei PLs.  Ps. flavipulchra JL1Sm was the only 
species tested that significantly decreased the survival of L. vannamei PLs (p=0.008), 
but survival was only reduced from 97% to 83% during the 72 h treatment period.  
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Extending this treatment period further or applying Ps. flavipulchra to L. vannamei in 
an aquaculture setting could potentially reduce L. vannamei survival beyond the level 
found in this study.  Ps. flavipulchra was also found to induce 100% mortality in 
Artemia nauplii under the conditions used in this study.  Ps. flavipulchra should not be 
used in crustacean aquaculture due to the harmful effect this organism has on both 
Artemia sp. and L. vannamei identified in this study.  Ps. piscicida and Ps. arabiensis 
also induced 95% mortality in Artemia nauplii.  The harmful effect these organisms 
had on Artemia was not detected in L. vannamei, but is an indication that these 
bacteria could be harmful under different conditions or during an extended treatment 
period. 
Pretreatment of L. vannamei PLs with the six candidate probiont species before 
V. parahaemolyticus PSU5579Sm challenge revealed that both P. inhibens S4Sm and 
Ps. flavipulchra JL1Sm significantly increased PL survival compared to the 
challenged control (p<0.001).  Similar to the Artemia challenge experiments, 
pretreatment of PLs with P. inhibens S4Sm increased survival by 1.9-fold.  
Interestingly, while Ps. flavipulchra JL1Sm exhibited a small increase in mortality to 
L. vannamei PLs, this bacterium also increased the survival of PLs challenged with V. 
parahaemolyticus PSU5579Sm.  Of the candidate probionts tested, Ps. flavipulchra 
JL1 produced the largest ZOI against V. parahaemolyticus.  Although Ps. flavipulchra 
JL1Sm may negatively affect L. vannamei, it also appears to prevent V. 
parahaemolyticus from causing AHPND.  Ps. flavipulchra was far more harmful to 
Artemia nauplii than to L. vannamei PLs, which explains why a level of protection 
from V. parahaemolyticus was not detected in the Artemia sp. model.  As in the 
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Artemia sp. model, Ps. piscicida JL15Sm, Ps. arabiensis JL29Sm, B. denitrificans 
JL63Sm, and B. pumilus RI06-95Sm did not significantly increase the survival of L. 
vannamei PLs challenged with V. parahaemolyticus PSU5579Sm (p>0.051). 
These results indicate that the Artemia sp. model used in this study makes a 
good substitute for L. vannamei to study the effects of probiotics on AHPND.  The 
Artemia sp. model successfully identified P. inhibens S4Sm as being the only 
candidate probiont tested that is not harmful to crustaceans and can prevent AHPND.  
The Artemia sp. model also identified B. pumilus as having no effect on AHPND.  
Artemia were also more sensitive to the harmful effects of Pseudoalteromonas spp. 
and B. denitrificans than L. vannamei, demonstrating that these organisms may be 
harmful to shrimp if used under different conditions and/or long-term. 
Phaeobacter inhibens S4Sm is the only candidate probiont tested that is not 
harmful to L. vannamei PLs and can significantly increase the survival of both L. 
vannamei PLs and Artemia nauplii challenged with AHPND V. parahaemolyticus.  
Although twelve strains of candidate probionts produced promising results in vitro, 
our study showed that biofilm formation and growth-inhibiting activity toward a 
particular pathogen in vitro are not necessarily predictive of how a candidate probiont 
would perform in vivo.  This study found that under the conditions used, Ps. 
flavipulchra, Ps. piscicida, and Ps. arabiensis were lethal to Artemia sp. and Ps. 
flavipulchra was also harmful to L. vannamei.  It has been shown that some 
organisms, such as Pseudoalteromonas spp., that produce compounds inhibitory 
toward the growth of bacterial pathogens are also toxic to eukaryotic organisms [29, 
60, 61].  Neu et al. [29] determined that Pseudoalteromonas luteoviolacea strains 
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S2607 and S4060 produce the antibacterial compound pentabromopseudilin which is 
lethal to Artemia nauplii.  Ps. piscicida S2049 has also been shown to produce several 
bromoalterochromides [62] which are inhibitory toward Bacillus subtilis [63] and 
toxic to sea urchins [62].  Ps. rubra produces prodigiosin [64] which is antagonistic 
toward bacteria [65] and toxic to algae [66] and eukaryotic parasites [67]. 
Bowmanella denitrificans did not significantly decrease the survival of Artemia 
sp. or L. vannamei in probiotic controls, but did decrease the survival of these animals 
when challenged with V. parahaemolyticus, indicating that this organism potentiates 
V. parahaemolyticus infection.  V. parahaemolyticus possess two type VI secretion 
systems (T6SS) [68] which may allow V. parahaemolyticus to kill other bacteria and 
potentially mediate host colonization.  This effect has been shown for Vibrio cholerae 
which uses a T6SS to perturb the host’s natural microbiota and enhance the pathogen’s 
colonization of the host [69].  By killing bacteria colonizing the host’s gastrointestinal 
tract, V. cholerae opens up space which it can then colonize.  Gildberg et al. [70] 
demonstrated potentiation of the fish pathogen Aeromonas salmonicida by lactic acid 
bacteria.  The lactic acid bacteria were able to colonize the intestine of Atlantic salmon 
(Salmo salar) fry, but surprisingly increased the mortality of fry challenged with A. 
salmonicida [70]. 
Bacteria belonging to the genus Bacillus are some of the most common 
organisms used as probiotics in aquaculture, have been shown to be effective 
probiotics for penaeid shrimp, and can reduce incidence of disease caused by Vibrio 
spp. [16, 22, 71, 72].  However, this study found that in the conditions used in these 
experiments, B. pumilus was not able to reduce the mortality rate of Artemia sp. or L. 
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vannamei challenged with AHPND V. parahaemolyticus.  This lack of in vivo 
protection by a candidate probiont with promising in vitro activity has been shown 
before.  For example, Pseudomonas fluorescens can protect rainbow trout 
(Oncorynchus mykiss) from Vibrio anguillarum [73] but does not protect salmon (S. 
salar) from A. salmonicida, even though P. fluorescens can inhibit the growth of A. 
salmonicida in vitro [45].  This emphasizes the need to test candidate probionts for 
each unique host-pathogen combination in vivo before application in aquaculture. 
Members of the genus Phaeobacter have been shown to be effective probiotic 
organisms for the protection of cod and turbot larvae from the pathogen V. 
anguillarum [74, 75], as well as eastern oyster (Crassostrea virginica) larvae from the 
pathogens Aliiroseovarius crassostreae CV919-312
T
 and V. coralliilyticus RE22 [19, 
38].  This study demonstrated that P. inhibens S4Sm can also protect Artemia sp. and 
L. vannamei from AHPND V. parahaemolyticus.  The probiotic activity of P. inhibens 
S4Sm has been studied and can be attributed to at least three factors: 1) excellent 
biofilm forming ability [38]; 2) production of the broad-spectrum antibiotic 
tropodithietic acid (TDA) [38]; and 3) ability to inhibit the quorum sensing-dependent 
production of the virulence factor protease in V. coralliilyticus [76].  It has also been 
shown that resistance to TDA is hard to select [77], making it unlikely that pathogens 
with develop resistance to this probiotic over time. 
 In conclusion, P. inhibens S4Sm has great potential for application in whiteleg 
shrimp (L. vannamei) aquaculture for prevention of AHPND.  P. inhibens S4Sm is a 
strong biofilm former, showed antibiotic activity against V. parahaemolyticus in vitro, 
and provided protection to both Artemia sp. and L. vannamei in vivo.  Application of 
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P. inhibens S4Sm as a probiotic in shrimp aquaculture provides an advantageous 
alternative to the use of antibiotics for disease control. 
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Supplemental Data 
 
 
 
Figure S1. Survival of Artemia nauplii challenged immediately after hatching with 
suspected AHPND V. parahaemolyticus strains at 10
6
 CFU/ml.  Representative of one 
independent experiment with three technical replicates. 
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Figure S2. Survival of Artemia nauplii challenged 24 h after hatching with V. 
parahaemolyticus PSU5579 at 10
4
 or 10
5
 CFU/ml.  Representative of three 
independent experiments with three technical replicates per experiment.  Error bars 
equal one standard deviation. 
 
 
 
Figure S3. Survival of Artemia nauplii challenged 24 h after hatching with V. 
parahaemolyticus PSU5579 at 10
6
 or 10
7
 CFU/ml.  *, without the addition of 
YP30IOS.  Representative of one independent experiment with three technical 
replicates. 
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Figure S4. Effect of preincubation of Artemia nauplii with P. inhibens S4Sm at 10
5
 or 
10
6
 CFU/ml for 24 h on survival 48 h after challenge with V. parahaemolyticus 
PSU5579 at 10
5
 CFU/ml.  P. inhibens S4 was added at the start of the experiment and 
every 24 h.  Representative of one independent experiment with three technical 
replicates. 
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Figure S5. Survival of L. vannamei PLs 48 h post-treatment with V. parahaemolyticus 
PSU5579Sm applied at 10
5
 or 10
6
 CFU/ml at the start of the experiment (0 h), 24 h 
after the start of the experiment (24 h), or 24 h after the start of the experiment with 
the addition of 200 µg/ml streptomycin (24 h + Sm).  Representative of one 
independent experiment with three technical replicates. 
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Abstract 
Acute hepatopancreatic necrosis disease (AHPND) causes high mortalities in 
shrimp farms around the world (1-6).  We announce here the draft genome sequence 
of one AHPND strain of V. parahaemolyticus and describe virulence factors that may 
play a role in its pathogenicity. 
 
Body 
In 2009 an emerging disease now known as acute hepatopancreatic necrosis 
disease (AHPND) began to affect shrimp farms in southern China and has since spread 
to Vietnam, Malaysia, Thailand, and Mexico (1-6).  AHPND causes serious 
production losses in affected areas which negatively impacts local employment, social 
welfare, and international markets (5).  The causative agent of AHPND has been 
identified as Vibrio parahaemolyticus strains possessing the 69-kbp plasmid pVPA3-1 
encoding genes homologous to the Photorhabdus insect-related (Pir) toxin-like genes 
(pirA- and pirB-like) (6-8).  V. parahaemolyticus PSU5579 was isolated from shrimp 
farms located in southern Thailand during a disease outbreak and has been shown to 
induce high mortality rates via bath immersion at 10
5
 CFU/ml against whiteleg shrimp 
(Litopenaeus vannamei). 
V. parahaemolyticus PSU5579 was grown overnight in yeast-tryptone broth 
supplemented with 2% NaCl (LB20) at 27°C.  Genomic DNA was isolated using the 
Promega Wizard genomic DNA purification kit, and DNA was resuspended in 2 mM 
Tris-HCl buffer (Bio Basic).  Sequencing was performed at the Rhode Island 
89 
 
Genomics and Sequencing Center using an Illumina MiSeq Sequencer.  Sequence 
trimming was performed using CLC Genomics Workbench (version 9.5.3) resulting in 
2,743,364 paired-end reads averaging 192 bp in size.  Contigs with a coverage of ≥34 
were assembled using SPAdes genomic assembler (version 3.1.1) (9). The resulting 
contigs were processed using CLC Microbial Genome Finishing module using V. 
parahaemolyticus RIMD 2210633 as a reference genome. The draft genome consists 
of 44 contigs, with a total sequence length of 5,229,426 bp and a G+C content of 
45.3%. The draft genome included the complete 69,150 bp pVPA3-1 plasmid with a 
G+C content of 45.9%. Gene annotation was performed using Rapid Annotations 
using Subsystems Technology (RAST) and resulted in 4,840 open reading frames (10-
12). 
The genome of V. parahaemolyticus PSU5579 encodes a number of lytic 
enzymes including two secreted collagenases, one chitinase, one extracellular lipase, 
phospholipases A and C, nine hemolysins including cytolysin, leukocidin, and delta-
VPH, and six secreted proteases including an extracellular serine protease, three 
secreted trypsin-like serine proteases, and two extracellular zinc proteases including 
Vibriolysin.  Three adherence systems were identified: a type IV pilus, a mannose-
sensitive hemagglutinin type IV pilus system, and a symbiotic colonization and sigma-
dependent biofilm formation gene cluster.  Several iron acquisition systems were 
annotated including hemin, enterobactin, vibrioferrin, ferrichrome, and TonB, 
including the full complement of proteins responsible for the formation of the TonB-
ExbB-ExbD complex.  Three quorum-sensing systems are present: LuxMN, LuxSPQ, 
and CqsAS.  Six secretion systems were identified: one type I secretion system 
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(T1SS), one T2SS, one T3SS, one T2/4SS, and two T6SS.  The genome also encodes 
a capsular polysaccharide, one RTX toxin, and one beta-lactamase.  The 69 kbp 
pVPA3-1 plasmid encodes a conjugation system as well as the pirA- and pirB-like 
genes located on a 3.5 kbp fragment flanked by transposases.  The genome does not 
contain the tdh or trh genes associated with pathogenicity in humans (13). 
 
Nucleotide sequence accession numbers. This whole-genome shotgun project has 
been deposited in DDBJ/ENA/GenBank under the accession no. PEBT00000000.  The 
version described in this paper is the first version, PEBT01000000. 
 
ACKNOWLEDGMENTS 
This work was supported by an award from CP Foods to David R. Nelson, Marta 
Gomez-Chiarri, David C. Rowley, and John J. Mekalanos.  The funders had no role in 
the study design, data collection and interpretation, or the decision to submit the work 
for publication. We thank Wenjing Zhao at the Mekalanos Lab, Harvard Medical 
School for providing us with the V. parahaemolyticus PSU5579 strain. 
 
 
 
 
 
 
 
91 
 
REFERENCES 
1. NACA-FAO (Network of Aquaculture Centers in Asia-Pacific—Food and 
Agriculture Organization of the United Nations). 2011. Quarterly aquatic animal 
disease report (Asia and Pacific Region), 2011/2, April-June 2011. NACA, 
Bangkok. 
2. Lightner DV, Redman RM, Pantoja CR, Noble BL, Tran LH. 2012. Early mortality 
syndrome affects shrimp in Asia. Glob Aquacult Advocate Jan/Feb 2012: 40. 
3. Flegel TW. 2012. Historic emergence, impact and current status of shrimp 
pathogens in Asia. J Invertebr Pathol. 110: 166−173. 
4. Zorriehzahra MJ, Banaederakhshan R. 2015. Early Mortality Syndrome (EMS) as 
new emerging threat in shrimp industry. Adv Anim Vet Sci. 3(2s): 64-72. 
5. Bondad-Reantaso MG, Subasinghe RP, Josupeit H, Cai J, Zhou X. 2012. The role 
of crustacean fisheries and aquaculture in global food security: past, present and 
future. J Invertebr Pathol. 110:158−165. 
6. Han JE, Tang KFJ, Tran LH, Lightner DV. 2015. Photorhabdus insect-related (Pir) 
toxin-like genes in a plasmid of Vibrio parahaemolyticus, the causative agent of 
acute hepatopancreatic necrosis disease (AHPND) of shrimp. Dis Aquat Org. 
113:33-40. 
7. Kondo H, Tinwongger S, Proespraiwong P, Mavichak R, Unajak S, Nozaki R, 
Hirono I. 2014. Draft genome sequences of six strains of Vibrio parahaemolyticus 
isolated from early mortality syndrome/acute hepatopancreatic necrosis disease 
shrimp in Thailand. Genome Announc 2: e00221-14. 
8. Tinwongger S, Nochiri Y, Thawonsuwan J, Nozaki R, Kondo H, Awasthi SP, 
Hinenoya A, Yamasaki S, Hirono I. 2016. Virulence of acute hepatopancreatic 
necrosis disease PirAB‐like relies on secreted proteins not on gene copy number. 
Journal of Applied Microbiology. 1;121(6):1755-65. 
9. Nurk S, Bankevich A, Antipov D, Gurevich AA, Korobeynikov A, Lapidus A, 
Prjibelski AD, Pyshkin A, Sirotkin A, Sirotkin Y, Stepanauskas R, Clingenpeel 
SR, Woyke T, McLean JS, Lasken R, Tesler G, Alekseyev MA, Pevzner PA. 
2013. Assembling single-cell genomes and mini-metagenomes from chimeric 
MDA products. J Comput Biol. 20:714–737. 
10. Aziz RK, Bartels D, Best AA, DeJongh M, Disz T, Edwards RA, Formsma K, 
Gerdes S, Glass EM, Kubal M, Meyer F, Olsen GJ, Olson R, Osterman AL, 
Overbeek RA, McNeil LK, Paarmann D, Paczian T, Parrello B, Pusch GD, Reich 
C, Stevens R, Vassieva O, Vonstein V, Wilke A, Zagnitko O. 2008. The RAST 
server: Rapid Annotations using Subsystems Technology. BMC Genomics. 9:75. 
92 
 
 
11. Brettin T, Davis JJ, Disz T, Edwards RA, Gerdes S, Olsen GJ, Olson R, Overbeek 
R, Parrello B, Pusch GD, Shukla M, Thomason JA III, Stevens R, Vonstein V, 
Wattam AR, Xia F. 2015. RASTtk: a modular and extensible implementation of 
the RAST algorithm for building custom annotation pipelines and annotating 
batches of genomes. Sci Rep. 5:8365. 
12. Overbeek R, Olson R, Pusch GD, Olsen GJ, Davis JJ, Disz T, Edwards RA, 
Gerdes S, Parrello B, Shukla M, Vonstein V, Wattam AR, Xia F, Stevens R. 2014. 
The SEED and the rapid annotation of microbial genomes using subsystems 
technology (RAST). Nucleic Acids Res. 42:D206–D214. 
13. Shirai H, Ito H, Hirayama T, Nakamoto Y, Nakabayashi N, Kumagai K, Takeda 
Y, Nishibuchi M. 1990. Molecular epidemiologic evidence for association of 
thermostable direct hemolysin (TDH) and TDH-related hemolysin of Vibrio 
parahaemolyticus with gastroenteritis. Infection and immunity. 58(11):3568-3573. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
93 
 
 
Manuscript III 
 
Publication status: Preparing to submit to Genome Announcements 
 
Title: Draft Genome Sequence of Bowmanella denitrificans JL63, a Bacterium 
Isolated from Whiteleg Shrimp (Litopenaeus vannamei) that can Inhibit the Growth of 
Vibrio parahaemolyticus 
 
Authors: Jason P. LaPorte
1
, Edward J. Spinard
1
, Marta Gomez-Chiarri
2
, David C. 
Rowley
3
, David R. Nelson
1
 
 
Author affiliation: 
1
Department of Cell and Molecular Biology, 
2
Department of 
Fisheries, Animal and Veterinary Sciences, 
3
Department of Biomedical and 
Pharmaceutical Sciences, University of Rhode Island, Kingston, RI 02881, USA 
 
Key Words: Bowmanella denitrificans, Litopenaeus vannamei, antibiotic 
 
 
 
94 
 
Abstract 
Bowmanella denitrificans JL63 was isolated from a whiteleg shrimp 
(Litopenaeus vannamei) and was determined to have antibacterial activity against an 
acute hepatopancreatic necrosis disease (AHPND) strain of Vibrio parahaemolyticus.  
Here we report the draft genome sequence of this strain and identify genes potentially 
involved in its antibacterial activity. 
 
Body 
Bowmanella is a genus of bacteria of the family Alteromonadaceae within the 
Gammaproteobacteria which was first identified in 2006 (1).  Currently, only three 
species belonging to this genus have been described: Bowmanella denitrificans, B. 
pacifica, and B. dokdonensis.  B. denitrificans is a chemoorganotrophic bacterium 
capable of respiratory, but not fermentative metabolism (1).  B. denitrificans BD1
T
 
was the first strain of this species to be identified and is capable of anaerobic growth 
by carrying out denitrification while B. denitrificans S088 has been shown to produce 
a potent, heat-stable algicidal compound (1, 2).  B. denitrificans JL63 was isolated 
from a whiteleg shrimp (Litopenaeus vannamei) and can inhibit the growth of an acute 
hepatopancreatic necrosis disease (AHPND) strain of Vibrio parahaemolyticus on an 
agar surface, as determined by a zone of inhibition assay (3).  The B. denitrificans 
JL63 genome reported here is the first draft genome sequence of a Bowmanella. 
B. denitrificans JL63 was grown overnight in yeast-tryptone broth 
supplemented with 3% artificial sea salts (LB30IOS) at 27 °C.  Genomic DNA was 
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isolated using the Promega Wizard genomic DNA purification kit, and DNA was 
resuspended in 2 mM Tris-HCl buffer (Bio Basic).  Sequencing was performed at the 
Rhode Island Genomics and Sequencing Center using an Illumina MiSeq Sequencer.  
Sequence trimming was performed using CLC Genomics Workbench (version 9.5.3) 
resulting in 2,641,396 paired-end reads averaging 180 bp in size.  Contigs with a 
coverage of ≥34 were assembled using SPAdes genomic assembler (version 3.1.1) (4). 
The resulting contigs were processed using CLC Microbial Genome Finishing module.  
The draft genome consists of 39 contigs, with a total sequence length of 5,478,087 bp 
and G+C content of 50.4%.  Gene annotation was performed using Rapid Annotations 
using Subsystems Technology (RAST) and resulted in 4,980 open reading frames (5-
7).  The 16S rRNA gene of B. denitrificans JL63 is 99.8% similar to B. denitrificans 
BD1
T
, 99.0% similar to B. pacifica W3-3A, and 95.0% similar to B. dokdonensis 
UDC354.  B. denitrificans JL63 gyrB and rpoD are 98.6% and 98.3% similar to B. 
denitrificans BD1
T
 and 81.2% and 80.8% similar to B. pacifica W3-3A, respectively. 
The genome of B. denitrificans JL63 encodes several gene clusters potentially 
involved in the production of the following antibacterial compounds: colicin V (or 
bacteriocin), lanthionine, and the broad-spectrum antibacterial protein marinocine 
encoded by the lodAB operon.  The genome also encodes a secreted hemolysin-type 
calcium-binding bacteriocin, an antibiotic biosynthesis monooxygenase, a type VI 
secretion system (T6SS), and two iron acquisition systems, hemin and TonB, including 
the full complement of proteins responsible for the formation of the TonB-ExbB-ExbD 
complex.  Gene clusters for a type IV pilus as well as a mannose-sensitive 
hemagglutinin type IV pilus system are also present.  The genome contains gene 
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clusters for denitrification as well as nitrate/nitrite ammonification.  Three secondary 
metabolic gene clusters in the JL63 genome were predicted using antiSMASH (8).  
Gene clusters predicted to synthesize lantipeptide, bacteriocin, and a nonribosomal 
peptide were identified. 
 
Nucleotide sequence accession numbers. This whole-genome shotgun project has 
been deposited in DDBJ/ENA/GenBank under the accession no. PEBU00000000. The 
version described in this paper is the first version, PEBU01000000. 
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